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Abstract 
Individuals with Lynch Syndrome (LS) have a 25% to 75% lifetime risk of colorectal cancer 
and the cancer generally presents at an early age. Establishing the costs of strategies to 
prevent or delay the onset of cancer is, thus, desirable. This study compared the cost of two 
screening approaches - colonoscopy only (Strategy 1) versus genetic testing for LS followed 
by colonoscopy for the individuals that tested positive for LS (Strategy 2).  
A comparative cost analysis was conducted at a tertiary hospital, from the health provider 
perspective, using a micro-costing, ingredient approach. Probands that were selected, 
according to the Revised Bethesda Criteria, for genetic testing between 01 November 2014 
and 30 October 2015, and their first degree relatives (high risk relatives) were evaluated 
according to Strategy 1 and Strategy 2. Total costs per strategy were estimated and compared. 
Sensitivity analyses were performed on adherence rates to colonoscopy, positivity rates of 
relatives and discount rates. 
A total of 40 families were studied. The total cost for Strategy 1 amounted to R4 932 718 
($332 617) compared to R390 308 ($26 319) for Strategy 2 (Discount rate 3%; Adherence 
75% and Positivity rate of relatives 45%). Base case analysis indicated a difference of 92% 
less in the total cost for Strategy 2 compared to Strategy 1. Univariate sensitivity analyses 
showed that the difference in cost between the two strategies was not sensitive to changes in 
discount rates, adherence rates or positivity rates of relatives.   
Compared to colonoscopy screening only, colonoscopy combined with genetic testing 
presented a less costly option by identifying patients at high risk of colorectal cancer for 
screening. Testing of relatives should be facilitated since, compared to probands, genetic 
testing of relatives is less costly and is likely to have more benefit. Effectiveness of the 
screening programmes should be established through further research. 
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1. Background  and rationale  
 
1.1 Background  
Lynch Syndrome is clinically defined as a disorder that predisposes individuals to colorectal 
cancer, endometrial cancer and certain other cancers as a result of an underlying germline 
mismatch repair (MMR) gene mutation (Vasen et al. 2013). The disorder presents with high 
rates of multiple primary tumours, has an early age of onset and generally has an absence of 
typical risk factors (Vasen et al. 2013). Carriers of a mutation in any of the mismatch-repair 
(MMR) genes have a lifetime risk for colorectal cancer of 25% to 75%, compared to a 
lifetime risk 5% in the general population (Giardiello et al. 2014;  Snowsill et al. 2014; 
Vasen et al 2013). Lynch Syndrome includes individuals with existing cancers as well as 
those who have not yet developed cancer (Palomaki et al. 2009). 
Worldwide, colorectal cancer is noted as the third most common cancer and cause of cancer-
related deaths (Graham et al. 2012). In 2008, colorectal cancer accounted for more than 
600 000 deaths of which 70% occurred in low and middle income countries (Graham et al. 
2012). In South Africa, colorectal cancer is the fifth most common cancer, with 
approximately 4 697 new cases and 3 138 deaths reported in 2012 (National Health 
Laboratory Services: Globocan, 2015). Just over 50% of the new cases diagnosed and 41% 
of deaths were in persons less than 65 years old (Globocan 2015). The most common cause 
of hereditary colorectal cancer is Lynch Syndrome which accounts for approximately 3% to 
5% of all colorectal cancers (Bonadona et al. 2011; Snowsill et al. 2014). Other than the 
Lynch Syndrome register maintained by the University of Cape Town (UCT), there are few 
hereditary colorectal cancer registers in South Africa (Coetzee et al. 2013). To date, this 
register has recorded 61 families who mainly live in the Western Cape and Northern Cape 
areas (Voster, A: Division of Human Genetics: UCT, personal communication 2015). 
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1.2 Problem Statement 
Individuals with Lynch Syndrome have an elevated risk for developing cancer, with the 
highest risk for colorectal cancer (Snowsill et al. 2014). Estimated lifetime risks for 
colorectal cancer of 25% to 75% have been reported in many studies (Snowsill et al. 2014). 
Progression of adenoma to carcinoma is approximately five times more accelerated in 
individuals with Lynch Syndrome compared to sporadic and familial colorectal cancers 
(Snowsill et al. 2014; Vasen et al. 2013). Furthermore, colorectal cancer is generally 
asymptomatic until it has reached an advanced stage. For these reasons an effective 
screening programme is fundamental for early detection and successful management of 
colorectal cancer (Snowsill et al. 2014 & Vasen et al. 2013). 
Colonoscopy is the only screening programme that has proved to be effective for these 
individuals (Palomaki et al. 2009; Giardiello et al. 2014; Snowsill et al 2014). Two main 
advantages of appropriate screening are the early detection of cancer and consequently 
improved chances of curative treatment and secondly, the early detection of pre-cancerous 
lesions which allows for removal of the polyps before it progresses to cancer. Studies have 
shown that effective colonoscopy screening programmes reduced mortality by 65% to 72% 
(Palomaki et al. 2009; Giardiello et al. 2014; Snowsill et al 2014). Stupart et al. (2009) 
showed an 80% decrease in mortality in a South African study.  
Though sufficient evidence exists of the valuable benefits, formal colonoscopy screening 
programmes do not exist for individuals with Lynch Syndrome in South Africa (Thomson, 
S: Gastroenterology clinic: Groote Schuur hospitals, personal communication 2015). Public 
sector colonoscopy services, that service approximately 80% of the country’s population, are 
few and predominantly limited to secondary and tertiary level care. Colonoscopies are 
performed by medical or surgical gastroenterologists only, which contributes to the high cost 
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of the service. Due to the limited professional skills and services available, colonoscopies 
are generally not provided for screening purposes, but are performed on patients that already 
present with symptoms in order to exclude cancer (Thomson, S: Gastroenterology clinic: 
Groote Schuur hospitals, personal communication 2015).  
In a resource constrained environment, accurate prediction of individuals at high risk of 
colorectal cancer who will benefit from colonoscopy screening and leaving those at low risk 
of disease unexposed to potentially invasive screening procedures, will reduce the burden on 
services as well as optimise the use of scarce resources (Snowsill et al. 2014). Genetic 
testing is the only method to confirm a diagnosis for Lynch Syndrome and evidence 
suggested that it is a cost-effective and reliable strategy to identify individuals for 
colonoscopy screening (Snowsill, et al. 2014). Furthermore, genetic testing combined with 
immunological testing is the preferred strategy in terms of cost-effectiveness (Palomaki et al 
2009; Mvundura et al. 2010; Ladabaum et al. 2011; Snowsill, et al. 2014). The genetic 
testing service available for testing for Lynch Syndrome in patients from this study was 
provided on a research basis by the Human Genetics Research Unit in the Division of 
Human Genetics at the University of Cape Town (Ramesar, R: Division of Human Genetics: 
UCT, personal communication 2015). 
The lack of genetic testing and colonoscopy screening programmes pose a major drawback 
for the management of colorectal cancer in individuals with Lynch Syndrome. Determining 
the costs of providing these services is one of the key initial steps to assessing affordability 
and successful implementation of such services. 
1.3 Rationale and justification of study 
Apart from the high risk rate associated with colorectal cancer in LS, these cancers occur, 
generally, before the age of 50 years with numbers beginning to increase noticeably from the 
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age of 30 years (Bonadona et al. 2011; Cohen et al. 2014; Snowsill et al 2014). This age 
range includes persons that are financially independent, economically active and support 
families.  Preventing or delaying cancer onset, by appropriate screening strategies, would 
have health related, social and economic benefits for the country. It is, therefore, important 
to establish the cost of colonoscopy screening options as this would contribute to assessing 
affordability of such services to the health service provider. 
Colonoscopy screening and clinical genetics have a strong emphasis on early detection and 
prevention of cancers which is in line with the National Department of Health’s strategic 
objective of enhanced wellness through primary, secondary and tertiary prevention 
(Department of Health: Western Cape. 2014). Also, the Western Cape Department of Health 
issued a genetic services policy framework for the province (Department of Health: Circular 
H212/2014). Services listed within the packages of care included genetic risk based on 
family history for e.g. cancers. The policy further specified the development of a “Rare 
Disease Policy” which should address the equitable rationing of scarce resources 
(Department of Health: Circular H212/2014). Results from this study would contribute to 
this policy by informing on the resource allocations and affordability of an effective Lynch 
Syndrome genetic testing programme.  
No published study has assessed the cost implications associated with providing a formal 
public sector colonoscopy and genetic testing screening service for patients with Lynch 
Syndrome in South Africa. Evidence with regards to screening strategies for Lynch 
Syndrome suggested that targeted screening is cost-effective as opposed to no screening 
(Snowsill et al. 2014). Almost all of these studies were conducted in high income countries 
and generalisability to the South African context is impractical as cost-effectiveness is 
largely context specific and linked to available resources and practices. (Buchanan et al 
2013; Gray et al. 2012; Drummond et al. 2005; Snowsill et al 2014).  
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This study, therefore, aims to collect and analyse primary data specific to the South African 
context in order to compare the cost implications of two screening options from a provider’s 
perspective; i.e. colonoscopy screening for all Lynch Syndrome-suspected individuals 
versus targeted colonoscopy screening for the individuals diagnosed with Lynch Syndrome 
after genetic testing. Based on literature (Snowsill et al. 2014), it is hypothesised that 
targeted colonoscopy screening will reduce the number of patients requiring colonoscopy 
and will, thus present a less costly option.  
 
1.4 Literature review 
 
1.4.1 Lynch Syndrome 
Lynch Syndrome (LS) is an autosomal dominant disorder that predisposes individuals to 
cancers, especially colorectal cancer (Cohen et al. 2014). A defect in the MMR system leads 
to loss of function of the entire MMR complex and an inability to restore base-base 
mismatches and small insertions and deletions in DNA sequences. This results in an 
accelerated accumulation of genetic mutations which often progresses to cancer. Mutations 
were found in one of the four MMR genes, MLH1, MSH2, MSH6 or PSM2. More recently, 
deletions of the 3’ end of EPCAM were reported and these deletions resulted in epigenetic 
hypermethylation of the MSH2 promoter, thereby resulting in LS (Cohen et al. 2014).    
  
The risks of developing cancers associated with LS are continuing to evolve with the 
increased application of germline testing and these risks are highly MMR gene mutation and 
sex dependent (Snowsill et al. 2014; Cohen et al. 2014). For men the risk of colorectal 
cancer was reported to be higher than for women (38% - 45% vs 31% - 35%) (Bonadona et 
al. 2011; Giardiello et al. 2014). The highest risks, in the region of 40% to 70%, are 
associated with individuals with MLH1 and MSH2 mutations, with lower risks reported for 
MSH6 (10% - 22%) and PMS2 (15% - 22%) (Bonadona et al. 2011; Steinke et al. 2013; 
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Vasen et al. 2013; Giardiello et al. 2014). MHL1 and MSH2 mutations were identified in the 
cohort recorded on the UCT DNA database, but to date no MSH6, PMS2 and EPCAM 
mutations were identified (Voster, A: Division of Human Genetics: UCT, personal 
communication 2015). The MMR mutation distribution in the UCT cohort indicates a 
population that falls in the highest risk category, reinforcing the need for an effective 
screening programme.  
Unlike sporadic cancers that generally occur approximately after the age of 60 years, LS- 
associated colorectal cancers have an earlier onset, i.e. < 50 years old, and may occur as 
early as 25 years of age (Giardiello et al. 2014; Cohen et al. 2014; Vasen et al. 2013). The 
estimated cumulative risk in carriers was shown to increase from the age of 30 years 
irrespective of the gene mutation (Bonadona et al. 2011). Around 15% - 20% of cancer 
survivors with LS will develop a second colorectal cancer within 10 years, 40% - 50% 
within 20 years and >60% within 30 years (Cohen, et al. 2014). In LS, polyps may progress 
to carcinoma within 2 to 3 years as opposed to 8 to >10 years in the general population. For 
these reasons, evidenced-based guidelines recommend colonoscopy every 1 to 2 years as 
opposed to every ten years as per the general population (Cohen, et al. 2014; Snowsill et al. 
2014; Giardiello et al. 2014; Vasen et al. 2013). 
 
1.4.2 Diagnosis and screening of Lynch Syndrome 
 
Diagnosis of Lynch Syndrome has progressed over the past two decades to include family 
history, histopathological characteristics and germline testing (Cohen et al. 2014).  
 
Though family history is an important element in assessing risk in the general population, 
neither the Amsterdam criteria nor the Bethesda criteria delivers the necessary sensitivity 
and specificity as a preliminary screening test (Vasen et al. 2013; Giardiello et al. 2014). 
Faecal occult blood tests (FOBTs) detect mainly asymptomatic cancers by detecting blood 
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from bleeding cancers (Coetzee 2013). Sensitivity of a single FOBT is about 30% as cancers 
bleed intermittently. Although cheap and non-invasive, the low sensitivity of FOBT is not 
ideal for screening for LS. Flexible sigmoidoscopy is less demanding technically and less 
invasive than colonoscopy and does not require full bowel preparation. This procedure 
allows for visualisation, removal of polyps and tissue biopsy of the left colon. However, 
about two thirds of LS-associated colorectal cancers appear proximal to the left colon and 
may be missed with sigmoidoscopy (Coetzee 2013).  
Colonoscopy allows for inspection of the entire colon and, if performed by a skilled 
professional, provides a sensitivity of up to 100% for detecting cancers and advanced 
adenomas (Coetzee 2013). There are no randomised controlled studies on routine 
colonoscopy screening (Coetzee 2013; Palomaki et al. 2009; Snowsill et al. 2014). However, 
observational studies (Level IIb evidence) exist that indicated a 62% reduction in incidence 
of colorectal cancer and 65% - 70% decrease in mortality (Palomaki et al. 2009). A South 
African study showed that colonoscopy screening produced better outcomes compared to no 
screening i.e. 11% vs 27% for colorectal cancer diagnosis and 2% vs 12% for death from 
colorectal cancer, respectively (Stupart et al. 2009). Colonoscopy is more invasive, requires 
sedation and bowel preparation, and has morbidity associated with this procedure (Coetzee 
2013; Snowsill et al. 2014). The most common, serious adverse events related to 
colonoscopy in the general population are death 0.08/1000, perforation (3.3/1000) and 
bleeding (11.1/1000) (Palomaki et al. 2009). 
Cost-effectiveness studies have recommended genetic testing as a strategy to identify high 
risk individuals for colonoscopy screening (Palomaki et al. 2009; Snowsill et al. 2014; 
Vasen et al. 2013). Germline testing is performed on blood and is diagnostic for LS. Partial 
reflex testing is done i.e. the result of a test done will determine whether another test will be 
performed and which test will be performed. Microsatellite Instability testing (MSI) or 
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Immunohistochemistry (IHC) was indicated as the preferred preliminary test to identify 
patients for genetic testing. IHC has the added advantage of directing germline testing to one 
of the four MMR genes (Palomaki et al. 2009; Snowsill et al. 2014; Vasen et al. 2013). MSI 
testing is labour intensive and expensive (Coetzee 2013). Performing BRAF testing on 
tumours with absent MLH1 staining would identify patients that would not benefit from 
MLH1 gene sequencing and, consequently, significant cost savings could be implicated. 
(Palomaki et al. 2009; Snowsill et al. 2014; Vasen et al. 2013). Locally, however, BRAF 
testing is technically not feasible (Voster, A: Division of Human Genetics: UCT, personal 
communication 2015). Recommendations on the most cost-effective germline testing have 
not yet been determined (Giardiello et al. 2014; Hampel 2010). Genetic testing counselling is 
recommended before and after undergoing germline testing, as well as follow-up counselling 
during colonoscopy screening sessions (Giardiello et al. 2014; Hampel 2010; palomaki et al 
2009).  
 
1.4.3 Cost effectiveness studies on screening strategies for Lynch Syndrome  
Research to date, on cost-effectiveness of screening strategies for Lynch Syndrome, has 
focused on high income countries and therefore generalisability to the South African 
population is problematic.  
A recent Health Technology Assessment included a systematic review of 32 cost-
effectiveness studies (Snowsill et al. 2014). Most of the studies were conducted from a 
health provider perspective and the majority of studies were set in the United States of 
America. Studies in the review used different tests or combination of tests, and therefore it 
was not possible to identify the most frequently used tests. Many of the studies did not meet 
the criteria from the Drummond checklist (Drummond et al. 2005). The review failed to 
provide consistency with regards to the strategies or tests that would be most cost-effective. 
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All studies, however, concluded that screening for Lynch Syndrome compared to no 
screening was cost-effective (Snowsill et al. 2014).  
Snowsill et al (2014) further conducted an economic evaluation comparing 8 screening 
strategies. Compared to no testing as the base case, MSI + BRAF V006 + genetic testing 
produced the lowest ICER. The more tests that were performed in sequence, the greater the 
specificity as well as the increased costs. Sensitivity analysis indicated that, even at low rates 
of acceptance of diagnostic tests and genetic counselling, Lynch Syndrome testing is cost-
effective compared to no testing. Sensitivity analysis performed on widely varying the 
number of relatives per proband, including no relatives, found screening for Lynch 
Syndrome more cost-effective than no screening. The majority of the diagnosing cost for the 
cohort was due to diagnosing the probands, as opposed to diagnosing the relatives. Costs 
were driven by the number of tests taken. Long term, the most influential cost driver was the 
cost of colonoscopies and diagnostic costs did not significantly influence the variation in 
costs between strategies. Preventative costs outweighed the increased savings in cost from 
colorectal treatment (Snowsill et al. 2014). 
Table 1 reflects the costs reported in various cost-effectiveness studies performed in 
different countries (Gross 2015).Total screening costs were around $2 242 to $3 345. One 
study was unusually high at a total cost of $6 312. Generally, the largest contributors 
towards the screening costs were the genetic testing for MLH1 and colonoscopy. Long-term 
the colonoscopy cost will be the main cost driver as the other costs are once-off costs. The 
lowest cost contributors were the genetic counselling costs and approaching relatives. The 
predictive tests for relatives were in all cases significantly lower than the genetic sequencing 
for MLH1 (identifying the mutation). This indicates the value of identifying a family 
mutation – i.e. relatives may be identified at a much lower cost for genetic testing and may 
benefit more from colonoscopy screening as they may not have cancer yet as opposed to the 
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proband who often present with cancer already. Furthermore, the cost of excluding a relative 
that tested negative for a mutation is far less than the cost of lifetime colonoscopy screening. 
Table 1: Base case estimates of costs of routine testing and colonoscopy for Lynch 

































































































































Mvundura et al. 
(2010) USA 
22 106 194 290 899 350 61 441 1043 3345 
% of total cost 0.66 3.17 5.80 8.67 26.88 10.46 1.82 13.18 31.18 100 
Ladabaum et al 
(2011) USA 
NR 112 198 300 942 118 492 610 690 2970 
% of total cost NR 3.77 6.67 10.10 31.72 3.97 16.57 20.54 23.23 100 
Sie et al (2007) 
Netherlands 
25 136 0 184 1184 77 353 430 206 2242 
% of total cost 1.12 6.07 0 8.21 52.81 3.43 15.74 19.18 9.19 100 
Snowsill et al 
(2014; 2015) UK 
0 0 103 366 714 103 265 368 911 2565 
% of total cost 0 0 4.02 14.27 27.84 4.02 10.33 14.35 35.52 100 
Severin et al 
(2014) Germany 
57 161 0 166 5268# 57 281 338 265 6312 
% of total cost 0.90 2.55 0 2.63 83.46 0.90 4.45 5.35 4.20 100 
Barzi et al (2015) 
USA 
NR 112 198 300 942 118 492 610 690 2970 
% of total cost NR 3.77 6.67 10.10 31.72 3.97 16.57 20.54 23.23 100 
NR: Not reported  * Not added to total (included in combined counselling and test)    
# Genetic testing costs is not higher in Germany. The German reimbursement for gene sequencing is an outlier.  
Adapted from Grosse 2015. Healthcare. 3, 860-878. 
2. Aims, objectives and conceptual framework  
2.1 Aim 
The aim of the study is to provide evidence of the relative cost of two screening options for 
colorectal cancer for persons with Lynch Syndrome for policy-making purposes in the 
public sector. Thus, costs for colonoscopy screening only (Strategy 1) will be compared with 
costs of conducting genetic testing for Lynch Syndrome followed by colonoscopy screening 
for the individuals that tested positive for Lynch Syndrome (Strategy 2).  
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1. To estimate the unit cost of colonoscopy. 
2. To estimate the weighted average unit cost of identifying the MMR gene mutation in 
patients with colorectal cancer.  
3. To estimate the weighted average unit cost of genetic testing for relatives of the proband.  
4. To use these unit costs to estimate and compare the total cost of screening for the two 
screening strategies for the same cohort of individuals.  
 
2.3 Conceptual framework 
Unit costs for colonoscopy and genetic testing will be estimated according to the utilisation 
patterns at the health facility and the expenditure incurred.  Unit costs for colonoscopy will 
be estimated by dividing the total annual cost of colonoscopy by the number of 
colonoscopies performed per annum.  Unit costs for genetic testing will be estimated by 
calculating the weighted average unit cost for genetic testing where the weighting will be 
estimated according to the proportion of patients that required a particular test or series of 
tests. These unit costs will be applied to the actual utilisation of potential LS patients 
(probands) and the total number of colonoscopies estimated per individual per lifetime per 
Strategy option in order to estimate the total costs for Strategy 1 and 2. Table 2 presents the 
conceptual framework for Strategy 1 and 2. 
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Table 2: Conceptual framework for estimating costs per screening strategy 
STRATEGY 1  
  
Colonoscopy screening only 
 
STRATEGY 2  
 
Genetic testing and colonoscopy screening for 
positively tested individuals 
 
1. Unit Cost: To estimate the unit cost of 
colonoscopy. 
 
2. Utilisation: To estimate the total number of 
colonoscopies required per lifetime for all 













3. Total cost = Unit cost x Utilisation: 
To estimate the total cost of screening for 
Strategy 1 (i.e. unit cost of colonoscopy x total 
number of colonoscopies required). 
 
  
1. Unit Cost A: To estimate the unit cost of 
colonoscopy. 
 
2. Utilisation A: To estimate the total number of 
colonoscopies required per lifetime for all 
individuals eligible for colonoscopy as per 
Strategy 2. 
 
3. Unit Cost B: To estimate the weighted 
average unit cost for:  
- genetic testing for diagnosing a proband  
- genetic testing for diagnosing a relative 
- genetic counselling 
 
4. Untilisation B: To estimate the total number 
of tests and genetic counselling sessions 
required. 
 
5. Total cost = (Unit cost A x Utilization A) + 
(Unit cost B x Utilisation B): 
To estimate the total cost of screening for 
Strategy 2 (i.e. unit cost of colonoscopy x total 
number of colonoscopies required + unit cost of 
genetic testing x total number of tests + unit cost 
of genetic counselling x total number of 
counselling sessions required). 
 
 




3.1 Study design 
The study design will be a comparative cost analysis, focusing on the collection of primary 
cost data, and will be conducted from a service provider perspective. A predominantly 
micro-costing, ingredient-based approach will be followed. The most relevant costs will be 
related to the resources used to perform colonoscopy and genetic testing. Costs of resources 
will be presented in 2016 South African rands and US dollars. 
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3.2 Setting and population 
The study will be undertaken at Groote Schuur hospital (GSH) in Observatory in the 
Western Cape, South Africa. GSH is a public sector, tertiary, academic hospital that 
provides sub-specialist level care. In South Africa, approximately 80% of the population 
seeks health care in the public sector (Department of Health 2014) and patients in this study 
were predominantly from the Western Cape and Northern Cape provinces. The colonoscopy 
service was provided by GSH while the genetic testing service for testing for Lynch 
Syndrome was provided on a research basis by the Human Genetics Research Unit in the 
Division of Human Genetics at the University of Cape Town (Ramesar, R: Division of 
Human Genetics: UCT, personal communication 2015). 
Patients on the UCT Lynch Syndrome DNA database (Ethics approval: HREC REF: 
217/2010) will be considered in the study (Voster, A: Division of Human Genetics: UCT, 
personal communication 2015). The patients (probands) on this database were selected if 
they met the Revised Bethesda Criteria after presenting with colorectal cancer or other LS-
related cancer. Due to advancements in genetic testing over the years, analysis of the data 
will be restricted to probands tested between 01 November 2014 and 30 October 2015 in 
order to ensure that the latest test methods are assessed to estimate costs.  Probands and their 
relatives will be analysed according to their age, relationship to the proband, alive status, 
tests performed, results of tests and surgical procedures performed. Probands and their first 
degree relatives (parents, children and siblings) that are eligible for colonoscopy screening 
will be considered for inclusion in the cost assessment. Persons that would not be eligible 
for colonoscopy screening would be excluded from the study, such as spouses, spouse’s 
family, deceased persons, persons under 25 years and over 60 years and persons that would 
not have colonoscopy screening (e.g. patients who had total colectomies). See Part D: 
Appendices: S1 Fig. and S2 Fig.) 
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3.3 Screening strategies 
The screening strategies considered were based on the services currently available at GSH and the 
collaboration with the Division of Human Genetics at UCT. Probands and first degree relatives 
will be considered as per the proposed protocol and current services available (Ramesar, R: 
Division of Human Genetics: UCT, personal communication 2015). LS-associated 
mutations have an autosomal dominant pattern and, therefore, there is a 50% chance that the 
mutation will be passed on to the first degree relative. 
Both screening strategies will be applied to the same cohort (see section 3.2 for inclusion 
and exclusion criteria) and total cost per strategy will be estimated. Thus, probands on the 
DNA database that were tested between 01 November 2014 and 30 October 2015, and their 
first degree relatives will be evaluated according to the two strategies below (See Part D: 
Appendices S1 Fig and S2 Fig): 
- Strategy 1 will involve estimating the cost for intensive colonoscopy screening for 
probands and their first degree relatives that are eligible for screening.  
- Strategy 2 will involve estimating the cost for genetic testing for all probands and the 
first degree relatives of LS-positive probands plus the cost of intensive colonoscopy 
screening for all individuals with a genetic test-confirmed diagnosis of Lynch Syndrome.  
Intensive colonoscopy screening involves colonoscopy screening biennially for patients 
under 30 years old and annually for individuals aged 30 years and older up to 60 years; 
thereafter colonoscopy will be every ten years (Voster, A: Division of Human Genetics: 
UCT, personal communication 2015). Individuals that tested negative on germline testing 
will be managed as per the general population i.e. colonoscopy every ten years after the age 
of 50 years. Taking into account the ages of the probands and their first degree relatives, the 
total lifetime number of colonoscopies for the two strategies will be estimated and costed.  
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Colonoscopy is a 30 to 60 minutes procedure performed in a dedicated, equipped room 
(Algar: GSH, personal communication 2015). A colonoscope is inserted into the rectum, 
through the colon and as far as the caecum. Prior to the procedure, patients are given a 
special cleansing preparation to clear the bowel. Sedatives may be given for pain control and 
to relax the patient. An intravenous cannula is prepared in the event that patients may require 
intravenous fluid or medication. The patient’s heart rhythm and blood pressure is monitored 
continuously. Post-colonoscopy, the patient is kept in an observation area for 1 to 2 hours. In 
the event of an incomplete colonoscopy, the procedure may be repeated at a later stage. 
(Algar: GSH, personal communication 2015) 
Genetic testing to diagnose Lynch Syndrome is complex due to the genetic heterogeneity 
and the preliminary screening tests that can be performed prior to genetic testing (Hampel 
2010). The reflex genetic testing procedure followed by the Division of Human Genetics at 
UCT for diagnosing Lynch Syndrome was applied in this study. (Voster: Human Genetics: 
UCT, personal communication 2015). Where possible, immunohistochemistry (IHC) testing 
is routinely performed as a first line preliminary screening test (Coetzee 2013). Negative 
staining of IHC testing i.e. absence of an MMR gene product, suggests a high risk for Lynch 
Syndrome. If the IHC shows presence of all genes, but a strong clinical suspicion exits, the 
patient will be offered MSI testing. MSI testing is expensive, labour intensive, time 
consuming and requires a skilled geneticist and, therefore, is only provided on request 
(Coetzee 2013). IHC and MSI are provided by the National Health Laboratory Services 
(NHLS). Germline testing is provided via NHLS and Division of Human Genetics 
Department at UCT (Voster: Human Genetics: UCT, personal communication 2015). All 
patients (probands) on the database undergo genetic testing. Genetic testing involves DNA 
isolation from whole blood, followed by testing for the 5 common founder mutations. A 
positive result for a founder mutation would be followed by Multiplex Ligation-dependent 
Probe Amplification (MLPA) analysis or Sanger sequencing on a different day and different 
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blood sample for quality assurance (confirmation) purposes. In the case of a known 
mutation, that is not a common founder mutation, Sanger sequencing would be done, and 
this would be repeated on a separate day on a separate blood sample for quality assurance 
purposes. On identification of the MMR gene mutation in the index patient, the relatives 
would be offered germline testing for the identified MMR mutation. BRAF V600E is not 
offered due to its technical complexity. Individuals identified for genetic testing should 
receive genetic counselling by a trained genetic counsellor prior to and post undergoing 
genetic testing, as well as during colonoscopy screening. In addition, informed consent for 
genetic testing is a prerequisite to genetic testing. All positive probands and their first degree 
relatives would be offered intensive colonoscopy screening (Voster: Human Genetics: UCT, 
personal communication 2015; Hampel 2010). 
 
In summary, IHC is performed on probands with suitable colon tissue available for this test. 
All probands would receive screening genetic tests i.e. the Common Founder test or a 
Sequencing test for those with a known family mutation that is not a founder mutation. Only 
probands with positive screening tests would receive quality assurance / confirmatory tests 
i.e. a digestive test and / or another sequencing test. See Part D: Appendices: S3 Fig for the 
flow diagram of tests performed.    
 
3.4 Cost analysis  
Costs are the value of the resources required to provide a particular service (Gray et al. 
2012). The costs for performing a colonoscopy and genetic testing will be identified, 
quantified (measured) and valued.  
Table 3 displays a summary of the categories of costs / resources that will be considered, 
together with the methods that will be used to collect, measure and value these costs.   
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Table 3: Identification, measurement and valuation of costs 
TYPE OF 
COST IDENTIFICATION MEASUREMENT VALUATION 
Capital 
cost 
Categories Costing method Source of data Valuation 
method 
Source of data 
Building Colonoscopy room, recovery, 
consulting room, waiting room, 
toilet, prep room, laboratory 
space, laboratory extraction 
room, etc. 
Proportion of square 
metres floor space 
used or proportion 
of activities 
Observation and 














Medical & genetic testing 
equipment, , heart monitor, 
colonoscope, processor, gel 
documentation, workstation, 
computer, thermal cycler, 
centrifuge, refrigerators, other 
laboratory equipment  
 
Proportion of 
lifetime use or 








contract prices  
 











Tables, chairs, cabinets, 












rental fees  
 
WCGH Depart of 
Public Works, 





Categories Costing method Source of data Valuation 
method 
Source of data 
Personnel Administration, clinician, 
nurses, managers, genetic 
counsellors, laboratory 
technicians, medical technician, 
general assistants 
Proportion of 
working hours spent 
on colonoscopy, 




Gross salary per 
month, including 
benefits (Cost to 
company) 
WCGH PERSAL 











telephone, stationery, water, 
laundry, etc.). Maintenance of 





proportion of floor 






















Needles, syringes, gloves, 
swabs, specimen jars, cleaning 
supplies, disinfectants, aprons, 
stationery, polypectomy snares, 
























Sedation, premed, bowel 


























Laboratory tests, genetic tests, 
DNA isolation, MSI test, IHC 



















records, BAS report, 
contracts, NHLS, 
UCT procurement 
records & finance 
report, suppliers’ 
price list 
BAS: Basic Accounting System;   CSIR: Council for Scientific and Industrial Research;  DBSA: The Development Bank of South Africa;    
DPSA- COLA: Department of Public Service and Administration Cost-of-Living Adjustments;    GSH: Groote Schuur hospital;  
IHC: Immunohistochemistry;    MSI: Microsatellite Instability;  NDOH: National Department of Health;     
NHLS: National Health Laboratory Services;    PERSAL: Personnel and Salary System;      WCGH: Western Cape Government – Health; 
WCGH SCM Supply Chain Management;  UCT: University of Cape Town    
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Costs will be estimated in terms of recurrent costs and capital costs. Recurrent costs will 
generally be estimated by using an ingredient-based approach i.e. costs will be calculated by 
multiplying unit costs by the quantities or proportion of resources used. Any item used for 
longer than one year will be considered a capital cost (Gray et al. 2012). The equivalent 
annual cost of a capital item will be estimated by annuitizing the initial capital expenditure 
using a discount rate of 3% (Glick et al. 2007; Mangham 2009; Drummond et al. 2005). 
Useful life-years for capital items will be assumed as follows - buildings: 30 years; major 
equipment: 5 to 10 years; furniture: 10 years; vehicles: 3 – 5 years and small equipment: 1 – 
5 years; training: 10 years (Drummond et al. 2005; Somda et al. 2007). An 8% mark-up is 
the standard included in Department of Health contracts for the maintenance of equipment 
and will be considered for calculating maintenance costs of equipment. (Rademeyer: Deputy 
Director: WCGH Department of public Works, personal communication 2015). 
For shared costs e.g. overheads, departments or resources that directly affect the service to 
the patient will be identified. A unit of output e.g. number of hours for staff costs, square 
meters floor space for housekeeping, etc. will be determined and allocation of costs will be 
done in terms of the proportion of units of outputs used to provide the service. (Drummond 
et al. 2005; Gray et al. 2012). 
For personnel costs, a unit cost (cost per minute) for the different cadre of staff will be 
determined by dividing the annual total cost to company by the annual total working 
minutes of the staff member. 
Major adverse events are rare (Palomaki et al. 2009) and will be excluded from the study. 
Grosse (2015) reported in a review that differences in assumptions regarding complications 
as well as excluding complications had little influence on incremental cost effectiveness 
ratios (ICERS). 
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Data from colonoscopies performed on the study cohort indicated that approximately 6% of 
colonoscopies may require repeat colonoscopies (Algar: GSH, personal communication 
2015). Repeat colonoscopies will be included in the average unit cost for colonoscopy. 
The cost of genetic testing may vary from patient to patient depending on the type of test 
and the number of tests that were conducted on the patient. The unit cost for genetic testing 
per proband or first degree relative will, therefore, be estimated by calculating the weighted 
average cost for genetic testing where the weighting will be estimated according to the 
estimated proportion of patients that required a particular test or series of tests. Costs for 
tests performed by the NHLS (e.g. IHC and MSI) will be obtained from expenditure reports 
from Groote Schuur hospital or from the NHLS price lists. 
Discount rate should be applied for programmes with differential timing of cost outlays.  A 
discount rate of 3%, consistent with existing literature, was used as per the recommendations 
by Drummond et al, 2005. The South African Department of Health recommends that 
undiscounted costs should be reported on as well as a baseline annual discount rate of 5% 
(Department of Health; Government Gazette No. 36118). Thus, sensitivity analysis was 
done on discount rates of 0% and 5%.  
The unit cost data of colonoscopy and genetic testing, as well as the total lifetime number of 
colonoscopies required will be used to estimate the total cost for the cohort for Strategy 1 
and Strategy 2. 
Data will be collected in 2015 by interviewing staff, folder reviews and observing activities. 
Costs will also be obtained from expenditure records, tender documents, purchase contracts, 
service agreements and the Department of Health (DOH) financial year 2014/2015 
expenditure records and UCT 2015 expenditure and financial records. DOH costs will be 
used to value resources and where not available, market prices will be used. In the case of 
donated / volunteer resources, costs of these resources will be valued in terms of DOH costs, 
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and if not available, the market prices (or actual cost) will be used (Drummond et al. 2005; 
Gray et al. 2012). Examples of data collection and analysis tools are shown in the 
appendices (See part D: Appendices: S1 Table to S4 Table). 
 
3.5 Sensitivity analysis  
Uncertainties that would be most relevant in the study include the number of first degree 
relatives that would test positive and the number of colonoscopies required. The number of 
colonoscopies would depend on adherence to colonoscopy screening, and the number of 
relatives that tested positive.  Literature reported adherence rates ranging from 79% to 88% 
(Grosse et al. 2015). However, a study conducted in South Africa found an adherence rate as 
low as 25% in LS-diagnosed persons (Bruwer et al. 2013). Therefore, adherence rates of 
25%, 50%, 75% and 85% will be analysed. Positivity rates of 39% to 50% were reported in 
literature (Grasse et al. 2015). However, around 27% of the relatives on the DNA database 
tested positive. Sensitivity analysis will, therefore, be conducted on positivity rates of 30%, 
45% and 50%. Drummond et al. 2005 recommended that sensitivity analysis be performed 
on discount rates used commonly as well as no discount rate. Thus, discount rate of 5% and 
0% will be considered in the sensitivity analysis as per the recommendations in the South 
African Department of Health guidelines for pharmaco-economic submissions (Department 








The following assumptions will be made: 
- Mortality rates as per the general population were applied to both strategies. Risks of 
cancers that are part of the LS spectrum in this study population have not been 
published. The costs, therefore, may be overestimated. This exclusion is not expected 
to affect the direction of the hypothesis as the incidence of other cancers would be 
higher in the genetic tested LS-diagnosed group (Strategy 2) and thus potential 
increased mortality rate in this group. 
- All probands and first degree relatives of positive probands will be willing to 
undergo genetic testing. 
 
4.  Data analysis and management 
Costs will be estimated and presented as per the objectives in section 2.2: Aims and 
Objectives and section 3.4: Cost analysis. Data will be captured and analysed using 
Microsoft Excel®; and stored in password protected folders. Part D: Appendices: S1 Table 
to S4 Table shows examples of tools for data collection and calculations of costs for 
personnel, buildings, equipment and consumables; and Part D: Appendices: pages 3 – 5 
illustrate the assessment of eligible individuals for colonoscopies and genetic testing. See 
section 2.3: Conceptual framework for estimation of unit costs and total costs for 
colonoscopy and genetic testing. Completeness and accuracy of the data is the responsibility 
of the researcher. A data back-up system will be maintained. Data from the templates will be 
recorded directly onto the database. The data will be cleaned and once all queries have been 
addressed, the database will be locked.  
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5. Ethical considerations  
5.1 Potential benefits and risks 
This study poses no potential risk or harm to the participant. This study is unlikely to benefit 
the individual participants directly. Important indirect benefits will be that the information 
may direct future resources towards the management of Lynch Syndrome in terms of genetic 
testing and colonoscopy screening, and prevention of inappropriate exposure to invasive 
colonoscopy procedures. 
5.2 Autonomy and informed consent 
Informed consent will be obtained from staff and informants that assist with information and 
access to documents related to costs. Informants and staff will be made aware that 
participation and withdrawal from the study is voluntary. 
5.3 Confidentiality 
Privacy and confidentiality will be assured. Information will be captured under unique 
identifiers and no names will appear on forms or in the database. No personal identifiers will 
be used in the analysis or appear in any publication or report. All electronic data will be 
password protected and accessible only to the study team. Paper forms will be stored in a 
locked cupboard. 
5.4 Ethical approval 
This protocol will be submitted to the University of Cape Town Human Research Ethics 
Committee (UCT HREC) for approval. The protocol will also be submitted to the relevant 
Provincial DOH authorities for review and permission to implement the study in areas of 
their jurisdiction. 
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6. Publication and dissemination 
The study will be submitted for the Masters in Public Health: Health Economics degree. The 
findings of the study will also be submitted to the relevant Department of Health officials in 
the Western Cape, Division of Human Genetics: UCT, Groote Schuur hospital and persons 
that participated in the study. A manuscript will be drafted for publication. 
 
7. Logistics 
The study will be conducted over a 12 month period. The activities and time lines are shown 
in Table 4 
Table 4: Study time lines 
Activity 
 
Nov Dec Jan Feb Mar Apr May June July Aug Sept Oct Nov Dec - 
Mar 
Finalise protocol  
 




X              
Finalise data 
capture forms 




 X X X X          
Collect data: 
Review records, 
tender docs, etc. 
  X X X X         
Capture data on 
database 
      X X       
Analyse & clean 
data 
        X X X    
Write up 
 
           X X  
Complete 
dissertation 
             X 
Submission 
 
             X 
 
8. Budget 
The study will be self-funded. 
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A comparative cost analysis of two screening strategies for colorectal cancer in Lynch 




PART B: Literature review 
1. Introduction 
A comparative cost analysis will be conducted for screening options for colorectal cancer 
in Lynch Syndrome (LS), with a focus on the available options for South Africa. 
Objectives of this literature review will, thus, seek to inform on the following: 
- An overview of LS and its impact within the South African context. 
- Effective diagnosing and screening options for colorectal cancer in LS. 
- Economic evaluation and cost implications of screening strategies for colorectal 
cancer in LS. 
- Economic evaluation methodology for assessing costs, with a focus on screening 
strategies for colorectal cancer in LS. 
This literature review, firstly, describes key aspects of Lynch Syndrome (LS) in terms of 
incidence, risks and clinical features of the disease in order to inform on the impact of LS 
on society. The next section briefly describes screening options for colorectal cancer in LS 
and this is followed by economic evaluations conducted on various screening strategies. 
Lastly, approaches to economic evaluations and cost analysis for priority setting and 
resource allocation in public health are discussed. The review concludes with describing 
the existing gaps in literature with regards to the purpose for this study.  
A search filter was used to identify literature for in PUBMED, Google Scholar and the 
Cochrane Collaboration database. Search terms were based on search terms used in 
evidence-based guidelines and systematic literature reviews (Palomaki et al. 2009; 
Giardello et al. 2014; Snowsill et al. 2014). Search terms included Lynch Syndrome, health 
economics, cost analysis, cost-effectiveness, genomics, genetic testing, hereditary cancer, 
colorectal cancer, mismatch repair, MMR, HNPCC, hereditary nonpolyposis colorectal 
cancer, colorectal neoplasm, colonoscopy and colorectal cancer surveillance. Due to 
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advancements in technology and management of Lynch Syndrome, publications retrieved 
on these subjects were restricted to periods after 2004 (Palomaki et al. 2009; Giardello et 
al. 2014). The language filter was restricted to English publications. Four evidence-based 
guidelines (Palomaki et al. 2009; Giardello et al. 2014; EGAPP 2009; Vasen et al 2013) 
and one Health Technology Assessment (HTA) (Snowsill et al. 2014) formed the bases of 
the review. The information across these documents was generally consistent in terms of 
prognosis, risks, guidelines and similar studies were cited. Stupart et al (2009) provided 
observational study data on outcomes of colonoscopy surveillance for the population of 
this study. All studies on outcomes of colonoscopy were observational. Information on 
costs was contained in observational studies on cost-effectiveness; and these costs were 
summarised in a review by Grosse (2015) and the HTA (Snowsill et al 2014).   Adherence 
data were obtained from two studies conducted in South Africa (Bruwer et al 2013; 
Bruwer et al 2013). Information on economic and cost analysis methodology were derived 
predominantly from Drummond et al (2005) and Gray et al (2012) and published studies 
on cost analysis of health programmes (Subramanian et al 2010; Sinanovic et al 2006; 
Sinanovic et al 2003). Around 14 studies conducted on Lynch Syndrome in South Africa 
were retrieved. However, these studies involved the clinical aspects of the disease (Stupart 
et al 2009; Wentwink et al 2010; Hitchins et al 2011; Hameed et al 2005); quality of a 
mobile colonoscopy service (Anderson et al 2005) and adherence and uptake rates (Bruwer 
et al 2013; Bruwer et al 2013). No local study involved the economic aspects related to 
providing a colonoscopy screening service for Lynch Syndrome individuals. Grey 
literature such as policy documents (National Department of Health: Sub-directorate 
Human Genetics, 2000), standard operating procedures for genetic testing (Division of 
Human Genetics, 2015) and colonoscopy (GSH Gastroenterology Department, 2011), as 
well as draft protocol documents (GSH Gastroenterology Department, 2015) were 
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reviewed. Protocols on guidelines for the genetic testing procedures were not finalised at 
the time of the study. Thus, actual procedures, based on the draft protocols and observation 
at the time of the study, were assessed. 
 
2. Update on Lynch Syndrome 
 
The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) defined LS 
as an autosomal dominant disorder that predisposes individuals to certain cancers, with 
colorectal cancer as a major clinical consequence (Palomaki et al. 2009). Individuals with 
LS may or may not have cancer. EGAPP recommended that the previously used term, 
hereditary nonpolyposis colorectal cancer (HNPCC), be abandoned (Palomaki et al. 2009). 
LS is due to mutations in the mismatch repair (MMR) genes and persons with this disorder 
display high rates of multiple primary tumours, have an early age of onset of cancer and 
generally have an absence of typical risk factors (Vasen et al. 2013).  
 
Aldried Warthin first described Lynch Syndrome as far back as 1913 (Giardiello et al. 
2014; Wolf et al. 2013; Lynch et al. 2015). In 1966, Dr Henry T Lynch provided further 
insight when he described families with this hereditary colorectal predisposition. He found 
that 60% to 80% of these colorectal tumours were located in the proximal colon compared 
to about 30% in sporadic cancer High rates of synchronous and metachronous colorectal 
cancer with a Chrons-like pattern were also observed. Other LS-associated include 
endometrial cancer, cancers of the small bowel, stomach, hepatobiliary tract, pancrease, 
ureter, ovaries, renal pelvis, breast, prostate, sebaceous glands and glioblastoma, amongst 
others (Giardiello et al. 2014; Lynch et al. 2015). Diagnosis of LS has progressed over the 
past two decades to include differential diagnosing (family history, clinical phenotype, 
histopathological characteristics) and definitive diagnosing (germline testing). Since 2000, 
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over a period of 12 years, commercial genetic testing became available for the four MMR 
genes plus EPCAM. With the recent introduction of next-generation sequencing panels, 
additional genes are likely to be associated with LS (Giardiello et al. 2014; Wolf et al. 
2013; Lynch et al. 2015).  
 
3. Aetiology 
The underlying deoxyribonucleic acid (DNA) mismatch repair (MMR) gene defect was 
discovered in the early 1990’s (Palomaki et al. 2009; Giardiello et al. 2014; Wolf et al. 
2013). Mutations were found in one of the MMR genes; namely, MLH1, MSH2, MSH6 or 
PSM2. Up to 90% of mutations in LS are found in MLH1 and MSH2, and around 10% of 
mutations in MSH6. More recently, deletions of the 3’ end of EPCAM (directly upstream 
of the MSH2 gene) were reported and these deletions resulted in epigenetic 
hypermethylation of the MSH2 promoter, thereby resulting in Lynch Syndrome. MMR 
genes produce MMR proteins involved in detecting and correcting DNA replication errors. 
A defect in the MMR system leads to loss of function of the entire MMR complex and an 
inability to restore base-base mismatches and small insertions and deletions in DNA 
sequences. This results in an accelerated accumulation of genetic mutations which often 
progresses to carcinogenesis. Although mutations occur all over the genome, repetitive 
DNA sequences such as microsatellites are particularly prone to these mutations. This 
phenomenon of abnormal patterns of microsatellite repeats is referred to as microsatellite 
instability (MSI). MSI occurs in more than 90% colorectal cancers in LS and together with 
age of onset of disease and familial findings, MSI is a strong predictor of LS (Palomaki et 
al. 2009; Giardiello et al. 2014; Wolf et al. 2013).  
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Thus far, 19 different mutations in the MMR genes have been identified (as at Nov 2015) 
in the 62 families on the DNA database (HREC: REF: 217/2010) that formed part of our 
study. Of these, five common founder mutations have been associated with our cohort. The 
commonest mutation found in about 30% of these individuals was MLH1C12528T. 
 
4. Prevalence and risk 
 
Globally, colorectal cancer is noted as the third most common cancer and cause of cancer-
related deaths. It is estimated that the global annual incidence of colorectal cancer is more 
than 1 million (Graham et al 2012; Wentwink et al 2010). In 2008, colorectal cancer 
accounted for more than 600 000 deaths, of which 70% occurred in low and middle 
income countries. The most common cause of hereditary colorectal cancer is Lynch 
Syndrome which accounts for approx. 3% to 5% of all colorectal cancers (Graham et al. 
2012; Vasen et al. 2013; Snowsill eta al. 2014).  
 
In South Africa, colorectal cancer is the fifth most common cancer, with approximately 4 
697 new cases and 3 138 deaths reported in 2012 (National Health Laboratory Services: 
Globocan, 2015). Just over half of the new cases diagnosed and 41% of deaths occurred in 
individuals younger than 65 years of age (National Health Laboratory Services: Globocan, 
2015). Though adequate recording of colorectal cancer incidence exists in South Africa, 
estimates for LS are lacking as a formal reporting system for Lynch Syndrome does not 
exist (Coetzee et al. 2013). Other than the LS register (DNA database HREC: REF: 
217/2010) maintained by the University of Cape Town (UCT), there are very few, if any 
hereditary colorectal cancer registries in South Africa (Coetzee et al. 2013). With 
information from this register, Vergouwe, et al (2013) showed that inherited cancers 
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formed a three times bigger proportion of the total burden of colorectal cancer in a low-
prevalence area for colorectal cancer compared to high prevalence areas i.e. 10,5% vs 3%. 
He postulated that in low incidence areas such as South Africa, the prevalence of inherited 
cancers may be higher than the established values in the literature (Vergouwe et al, 2013).   
The risks of developing cancers associated with LS are continuing to evolve with the 
increased application of germline testing and these risks are highly MMR gene mutation 
and sex dependent (Bonadona et al. 2011; Giardiello et al 2014). A person with LS has a 
25% to 75% risk of colorectal cancer i.e. up to 1 in 3 people will develop colorectal cancer 
before the age of 70 years if there is no intervention. Though more recent studies have 
presented lower lifetime risks of 50%, this is still ten times higher than risks in the general 
population. Evidence suggests that MLH1 and MSH2 are the most widely distributed and 
has the highest risk of cancer. An evidence review performed by EGAPP (2009) reported 
that there is limited data that implies distributions of mutations of 32% in MLH1, 38% in 
MSH2, 14% in MSH6 and 15% in PMS2. Snowsill et al. (2014) reported distributions of 
mutations based on 12 624 observations internationally; i.e. 39% in MHL1, 34% in MSH2, 
20% in MSH6 and 8% in PMS2. This information, however, is context specific and bias in 
terms of local referral guidelines. In the UCT cohort that will be used in this study, MHL1 
and MSH2 mutations were identified, but to date no MSH6, PMS2 and EPGAM mutations 
have been identified (Voster, A: Division of Human Genetics: UCT, personal 
communication 2015). The highest risks, in the region of 40% to 70%, were associated 
with individuals with MLH1 and MSH2 mutations (Bonadona et al. 2011; Giardiello et al. 
2014). Lower risks were reported for MSH6 (10% - 22%) and PMS2 (15% - 20%). For 
men the risk of colorectal cancer was reported to be higher than for women i.e. 38% - 45% 
compared 31% - 35% (Bonadona et al. 2011; Giardiello et al. 2014). The MMR mutation 
distributions for the UCT DNA database cohort indicated a population that falls in the 
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highest risk category (predominantly MLH1  & MSH2), reinforcing the need for an 
effective screening programme. Currently, due to resource constraints, the Division of 
Human Genetics: UCT appropriately directed their genetic testing strategy predominantly 
on the common founder mutations in the MLH1 and MSH2 genes. 
In LS, the mean age at diagnosis of colorectal cancer is 41 to 66 years, whereas for the 
general population diagnosis is usually at around 69 years (Giardiello et al 2014; 
Bonadona et al. 2011; Cohen et al. 2014; Snowsill et al. 2014)). Furthermore, about half of 
colorectal cancer cases develop before the age of 50 years in LS compared to 10% in the 
general population. The estimated cumulative risks in carriers began to increase from the 
age 30 years irrespective of the gene mutation involved. Also, approximately 15% - 20% 
of cancer survivors with Lynch Syndrome will develop a second colorectal cancer within 
10 years, 40% - 50% within 20 years and >60% within 30 years. Progression of adenoma 
to carcinoma is accelerated in individuals with Lynch Syndrome compared to sporadic and 
familial colorectal cancers. In Lynch Syndrome polyps may progress to carcinoma within 
2 to 3 years as opposed to 8 to >10 years in the general population (Giardiello et al 2014; 
Bonadona et al. 2011; Cohen et al. 2014; Snowsill et al 2014). It is clear from the evidence 
that individuals affected by this disorder are in the age range of persons that are usually 
economically active and support families and, thus, the impact of this disorder stretches 
wider than just the individual. Delaying or preventing the onset of cancer would, therefore, 
be desirable. Furthermore, due to the autosomal dominant nature of the disorder, if one 
parent has an MMR mutation, this mutation will be inherited by his or her child i.e. the 
first degree relative (FDR) has a 50% chance of having LS (Snowsill et al. 2014). A first 
degree relative is a parent, child or sibling. EGAPP noted that there is limited, but 
promising evidence that testing / screening a patient for LS will impact on clinical 
management that will significantly improve health-related outcomes (Palomaki et al. 
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2009). Risk-reducing strategies may be offered such as early treatment of cancer, surgical 
interventions and cascade testing of relatives (Palomaki et al. 2009).    
 
5. Diagnosing Lynch Syndrome 
 
Diagnosing individuals with LS is key in the management of this disorder as these 
individuals can benefit from life-saving intensive cancer screening (Giardiello et al 2014; 
Vasen et al 2013; Lynch et al 2015). It is believed that LS is underdiagnosed due to the 
intricacy of diagnostic strategies, and thus, poor implementation of these strategies (Vasen 
et al. 2013). Accessibility and lack of awareness amongst the general population further 
contributed to the underdiagnosing of LS (Vasen et al. 2013).  
 
Technology for identifying LS is rapidly advancing, making it problematic to compare 
earlier studies and recent studies (Snowsill et al. 2014). Furthermore, heterogeneity 
amongst the studies and robustness of testing methods make pooling of data difficult. A 
number of strategies exist for diagnosing LS (Giardielloe et al 2014; Lynch et al 2015; 
Snowsill et al 2014; Vasen et al 2013). Differential diagnosis includes family history, 
histopathology and prediction models. Definitive diagnosis involves identification of the 
MMR mutation by genetic testing (Lynch et al. 2015).  Low specificity of tests would 
result in a high number of false positives and individuals may be informed that they have 
LS when they do not; and as a consequence be exposed to invasive and potentially 
hazardous procedures unnecessarily. Low sensitivity would result in a high number of 
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5.1 Family history and computational models 
 
Family history is still considered an important element in assessing risk in the general 
population (Palomaki et al. 2009; Giardiello et al. 2014; Vasen et al. 2013). The 
Amsterdam criteria exhibited a relatively low sensitivity of 22% and a specificity of 98% 
for diagnosing LS. The Revised Bethesda Criteria (See Table 1), also, did not deliver the 
necessary sensitivity (82%) and specificity (77%) as a preliminary screening test 
(Polomaki et al. 2009; Giardiello et al. 2014). Challenges with consistency in collecting 
information, time taken to collect information and accuracy of information collected 
contributed to the recommendation by EGAPP to remove family history as a preliminary 
test for patients newly diagnosed with colorectal cancer (Palomaki et al. 2009).  
 
Table 1: Revised Bethesda Criteria 
1. Colorectal cancer diagnosed at younger than 50 years. 
2. Presence of synchronous or metachronous colorectal cancer or other LS-associated tumours#. 
3. Colorectal with MSI-high pathologic-associated features (Crohn-like lymphocytic reaction, 
mucinous/signet cell differentiation, or medullary growth pattern) diagnosed in an individual 
younger than 60 years old. 
4. Patient with colorectal cancer and colorectal cancer or LS-associated tumour diagnosed in at 
least 1 first-degree relative younger than 50 years old. 
5. Patient with colorectal cancer and colorectal cancer or LS-associated tumour at any age in two 
first-degree or second-degree relatives. 
#LS-associated tumours include tumour of the colorectum, endometrium, stomach, ovary, pancreas, ureter, 
renal pelvis, biliary tract, brain, small bowel, sebaceous glands, and kerotoacanthomas. 
 
Giardiello et al. 2014. Gastroenterology, Volume 147, Issue 2, 2014, 502–526 
Computational models such as MMRpredict, MMRpro and PREMM are available online 
and perform better than the Revised Bethesda Criteria (Giardiello et al. 2014).  
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5.2 Immunohistochemistry 
 
Immunohistochemitry (IHC) testing is a preliminary test performed on tumour tissue and 
assists in identifying the MMR gene (MLH1, MSH2, MSH6 or PSM2) that is most likely to 
have a mutation (Giardiello et al. 2014; Snowsill et al. 2014; Hedge et al. 2013). IHC, thus, 
has the added advantage of directing germline testing to a specific gene. Patients with a 
negative stain would suggest high risk for LS and the individual may, therefore, be 
recommended for DNA analysis of the relevant gene. There is a lack of good quality 
evidence for estimating IHC sensitivity and specificity. The EGAPP reported, based on 
moderate evidence, sensitivity of approximately 83% irrespective of MMR gene involved, 
and specificity of 88.8% (with wide variations) (Palomaki et al. 2009; Giardiello et al. 
2014; Snowsill et al. 2014; Hedge et al. 2013). The Health Technology Assessment (HTA) 
conducted by the National Institute for Health Research reported IHC sensitivity that 
ranged from 73% - 100% and specificity that ranged from 12.5% - 100% (Snowsill et al. 
2014). As IHC is performed on tumour tissue, not all patients will be able to undergo IHC.  
 
5.3 Microsatellite Instability 
 
Microsatellite Instability (MSI) testing is a preliminary test performed on the tumour tissue 
to identify suitable candidates for germline testing (Snowsill et al. 2014). Patients with a 
high instability would proceed to immunohistochemistry or genetic testing as 10 – 15 % of 
patients with a high instability have sporadic colorectal cancer. Sensitivity and specificity 
may vary depending on the number of mononucleic markers included, test methodology 
and protocol for sample preparation. The HTA conducted by the National Institute for 
Health Research (2014) reported an MSI sensitivity range from 88% to 100%, but a lower 
specificity range from 68% to 84% (Snowsill et al. 2014). The EGAPP reported, based on 
11 
PART B: Literature review 
moderate evidence, sensitivities of approximately 89% (for MLH1 & MSH2) and about 
77% for MSH6 (Palomaki et al. 2009). About 5% of MSI have normal IHC results and 
therefore, it was suggested that both IHC and MSI be performed or to proceed directly to 
gene testing (Hampel 2009; Hedge et al. 2013). MSI testing is labour intensive, expensive 
and requires a skilled geneticist (Coetzee et al. 2013). 
 
5.4 BRAF V600E 
 
Most colorectal cancers with BRAF V600E mutations are associated with MSI positive 
results (Giardiello et al. 2014; Snowsill et al. 2014; Hedge et al. 2013). Almost always, an 
MMR mutation is not present when BRAF V600E mutation is found. Performing BRAF 
V600E testing on tumours with absent MLH1 staining would identify patients that would 
not benefit from MLH1 sequencing. Literature suggested that significant cost savings 
could be implicated as BRAF V600E testing is relatively inexpensive compared to MLH1 
sequencing and MLH1 is the most common MMR gene associated with absent IHC 
staining.  Sensitivity and specificity of BRAF V600E testing is estimated as 69% and 
100%, respectively, based on moderate evidence (Giardiello et al. 2014; Snowsill et al. 
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5.5 Genetic testing 
 
Advantages of genetic testing include:  
- confirmation of diagnosis in a proband / family,  
- confirmation of the diagnosis in an at-risk family member when the mutation is 
known and,  
- appropriate management can be offered for LS diagnosed individuals and those 
who tested negative for LS (Giardielo et al. 2014). 
Genetic testing in LS is complex as (i) there are a number of cancers to consider in the 
differential diagnosis, (ii) there is considerable overlap in phenotype and (iii) the testing 
involves a combination of germline tests and tumour tests (Hampel 2009). It is anticipated 
that Next-Generation Sequencing (NGS) will allow for simplification of this process as it 
will provide for the sequencing of all genes involved in LS-associated colorectal cancer in 
a panel; and at possibly a more reduced cost. (Hedge et al. 2013).  Testing strategies are 
illustrated in Figs 1, 2, 3 and 4 (Giardiello et al. 2014). Studies have shown that up to 25% 
of LS patients would be missed with the most generous clinical criteria and thus, EGAPP 
proposed universal testing for persons with colorectal cancer. Although this strategy was 
supported by the National Comprehensive Cancer Network and other groups, 
implementation is challenging, especially in resource constrained environments. In these 
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5.5.1 Universal testing 
Universal testing (Fig 1), as proposed by EGAPP, involves testing of all persons with 
colorectal cancer ≤70 years, and >70 years with a family history suggesting risk for LS 
(GRADE moderate quality evidence) (Giardiello et al. 2014). 
 
Fig. 1: Universal screening 
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5.5.2 Traditional testing 
Traditional testing involves selective genetic testing based on: 
- tumour displaying MMR deficiency; or  
- Revised Bethesda Criteria; or  
- Amsterdam Criteria; or  
- Uterine / endometrial cancer at <50 years; or  
- known mutation in family;  
- or / and personal risk ≥25% on prediction models.  
 
If the mutation is known (Fig. 2), a negative genetic test result for the mutation on the 
pedigree would indicate that the pedigree does not have LS (GRADE moderate quality 
evidence) (Giardiello et al. 2014). 
 
Fig. 2: Traditional testing strategy in the case of a known family mutation 
 
Giardiello et al. 2014. Gastroenterology, Volume 147, Issue 2, 2014, 502–526 
  
In the case of an affected person (i.e. has cancer) where the mutation is unknown (Fig. 3), 
IHC and / or MSI would be recommended. If these results do not suggest an MMR 
mutation, LS is excluded and no further testing is recommended. Conversely, if results are 
positive, genetic testing would be recommended (Giardiello et al. 2014). 
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Fig. 3: Traditional testing strategy in the case where the patient is clinically affected 
and mutation in the family is unknown 
 
Giardiello et al. 2014. Gastroenterology, Volume 147, Issue 2, 2014, 502–526 
In the case of an at-risk person (person with no cancer) where the family mutation is 
known, the at-risk person and relevant family members can be diagnosed for LS by genetic 
testing. Where the family mutation for the at-risk patient is unknown, it is suggested that 
an affected member be found and, if possible, evaluation of the tumour is suggested, which 
will direct genetic testing. If an affected member is not found, genetic testing can be 
performed as per Fig. 4.  
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Fig. 4: Traditional testing strategy in the case of an at-risk patient (do not have 
cancer yet) and an unknown family mutation 
 
Giardiello et al. 2014. Gastroenterology, Volume 147, Issue 2, 2014, 502–526 
 
Guidelines further recommended that genetic testing should not be offered to at-risk 
relatives until the mutation had been identified (Vasen et al. 2013; Giardiello et al. 2014). 
At-risk relatives can then undergo single mutation testing (predictive testing) for the 
identified gene which is less expensive and reliable. Relatives that have the mutation(s) 
and defer genetic testing should be treated the same as patients with Lynch Syndrome, 
whereas relatives that tested negative would follow screening frequency as per the general 
population. Literature suggested that for every proband, an average of 3 relatives could be 
tested for LS at a much lesser cost than the cost of testing a proband – thus, reflecting the 
benefit of identifying a proband (Vasen et al. 2013). Positivity rates of relatives of 39% to 
50% were reported for studies conducted in high income countries (Grosse et al. 2015). 
This means that for every two relatives tested, up to one may test positive.  
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5.5.3 Genetic testing procedures 
 
Various strategies have been applied to perform genetic testing for LS and to date there are 
no clear guidelines on best practice (Hampel 2010; Snowsill et al 2014). Practices can 
become fairly complex and may involve some or all of the following preliminary tests; 
IHC, MSI, or BRAF V600E. Genetic testing involves DNA extraction, polymerase chain 
reaction (PCR), restriction enzyme digest, Multiplex Ligation-dependent Probe 
Amplification (MLPA) and / or Sanger sequencing (Hampel 2010). 
- PCR amplifies the fragment of DNA carrying the site of the mutation (Hedge et al. 
2014);  
- Restriction enzyme digest specifically recognize the mutated DNA sequence and 
cut it.  The cut (mutation positive) and uncut (mutation negative) fragments are 
distinguishable on an agarose gel run in an electric field.  
- Sanger sequencing produces a graphic read out showing the exact site of the 
mutation. 
- Multiplex Ligation-dependent Probe Amplification (MLPA) detects 
deletions/insertions of whole exons of the respective gene(s) (Hedge et al. 2014).  
Snowsill et al (2014) reviewed the performance of genetic tests and resolved that 
Sequencing with MLPA was recognised as the gold standard for diagnosing LS. 
Standard operating procedures for genetic testing (Division of Human Genetics, 2015) 
informed on the actual procedures followed to perform the specific genetic tests for this 
study. However, the guidelines in terms of which tests to perform was not finalised (GSH 
Gastroenterology Department and UCT Division of Human Genetics, in progress). 
Therefore, actual procedures, based on the draft protocols and observation at the time of 
the study, was recorded for this study.  
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6. Genetic counselling & patient support 
Genetic counselling, by a trained health professional, includes pre-test, post-test and 
follow-up counselling with every colonoscopy screening session (Giardiello et al 2014). 
Appropriate standards and certifications are required as genetic counsellors have to be 
competent in order to deal with psychological, clinical, ethical and financial issues. 
Counselling involves informing patients, obtaining informed consent, constructing 
pedigree trees and disclosure of test results (Giardiello et al 2014). The most cost-effective 
approach, under limited funding, is to improve diagnosis in relatives of persons that have 
already been screened (Vasen et al 2013; Grosse 2015). Genetic counsellors play a key 
role in recruiting relatives for testing. Uptake rate of genetic testing in a local study were 
reported as reasonably high i.e. 97% and 74% for siblings and children, respectively 
(Bruwer et al. 2012).  
 
7. Screening for colorectal cancer 
Colorectal cancer is generally asymptomatic before the cancer has reached a relatively 
advanced stage (Vasen et al. 2013). The majority of colorectal cancers develop from a 
polyp, a premalignant form that may exist for years before symptoms of cancer manifest 
(Lynch et al. 2015). Individuals with LS can benefit from life-saving intensive screening 
and thus, it is crucial that these individuals be identified via an effective screening 
programme (Vasen et al. 2013). 
Faecal occult blood tests (FOBTs) detect mainly asymptomatic cancers by detecting blood 
from bleeding cancers (Coetzee et al 2013). Sensitivity of a single FOBT is about 30% as 
cancers only bleed intermittently. Although cheap and non-invasive, the low sensitivity of 
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FOBT is not ideal for screening for LS. Flexible sigmoidoscopy is less technically 
demanding and less invasive than colonoscopy and does not require full bowel preparation. 
This procedure allows for visualisation, removal of polyps and tissue biopsy of the left 
colon. However, about two thirds of Lynch Syndrome-associated colorectal cancers appear 
proximal to the left colon and may be missed (Lynch 2015; Coetzee et al 2013). 
 
Colonoscopy allows for inspection of the entire colon and, if performed by a skilled 
professional, provides a sensitivity of up to 100% for detecting cancers and advanced 
adenomas (Coetzee et al 2013). Two main advantages of appropriate screening are the 
early detection of cancer and consequently enhances prospects of curative treatment and 
secondly, the early detection of pre-cancerous lesions which allows for removal of the 
polyps before it can advance to cancer. There are no randomised controlled studies on 
routine colonoscopy screening. However, Level IIb evidence (well-designed quasi 
experimental study) exists that indicated a reduced incidence of colorectal cancer by 62% 
and 65% - 70% decrease in mortality (Jarvinen et al. 2009; Vasen et al. 2013). In a South 
African cohort from the same community as this study, Stupart et al (2008) showed that 
27% of patients in a no-colonoscopy screening group developed colorectal cancer as 
opposed to 11% in the group that received colonoscopy screening. In the same study, death 
from colorectal cancer occurred in 12% of the group that did not undergo colonoscopy 
screening compared to only 2% in the colonoscopy screening group (Stupart et al. 2008).  
Colonoscopy is more invasive, requires sedation and bowel preparation, and has morbidity 
associated with this procedure (Coetzee et al 2013; Snowsill et al 2014). The most 
common, serious adverse events related to colonoscopy in the general population are death 
0.08/1000, perforation (3.3/1000) and bleeding (11.1/1000) (Palomaki et al 2009). 
Compliance with colonoscopy is, therefore, lower compared with other procedures. 
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Adherence to colonoscopy ranged from 60% to 88% in studies conducted in high income 
countries (Gross 2015). Stupart et al (2008) reported an uptake of 72% in the South 
African cohort. A very low adherence rate to colonoscopy of 25% was reported in another 
South African study conducted on LS-positive persons over a 5-year period (Bruwer et al. 
2013). Uptake of colonoscopy depends on access to services, acceptance of services, 
awareness and availability of resources.  
Relatives without the mutation(s) should follow cancer screening guidelines as for the 
general population i.e. every ten years from the age of 50 years. (Giardiello et al. 2014; 
Snowsill et al. 2014). For LS individuals, most guidelines recommend that biennial 
colonoscopy should commence at the age of 20 - 25 years or two to five years before the 
age of the youngest person diagnosed with colorectal cancer in the family. Furthermore, 
biennial colonoscopy is recommended up to 29 years and annual colonoscopy for persons 
from 30 to about 60 years or when the risks of colonoscopy outweigh its benefit. It has 
also been recommended that, due to the reduced penetrance, individuals with MSH6 or 
PMS2 may commence colonoscopy screening as late as 30 years and 35 years, respectively 
(Giardiello et al. 2014; Snowsill et al. 2014). 
Public sector colonoscopy services in South Africa cater for approximately 80% of the 
country’s population and are few and limited to secondary and tertiary level care. 
Furthermore, these colonoscopies are only performed by medical or surgical 
gastroenterologists. Although there is evidence that simple endoscopy procedures could be 
provided by non-physicians safely and effectively, there is a paucity of data on non-
physicians providing colonoscopy (Day et al. 2014; Ruco et al. 2016). Due to the limited 
professional skills and services available, colonoscopies are generally not for screening 
purposes, but are performed on patients that present with symptoms in order to exclude 
cancer (Personal communication: Thomson, S: Gastroenterology clinic: GSH. 2015). 
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8. Cost analysis 
Genetic-based interventions are complex interventions that can guide clinical decision-
making in terms of accurate diagnosis, more focused treatment, potentially limit or prevent 
disease, prevent hazardous or unnecessary treatments, prolong life and overall promote 
health (Grosse et al 2008; Buchanan et al 2013). Furthermore, genetic information can 
guide patients and family members in terms of decision-making regarding their own 
health.  In most cases, genetic testing provides information for decision-making, but may 
not have any direct impact on mortality or morbidity. Screening, similarly, provides 
information for further action (e.g. polypectomy, curative treatments, etc.).  For both 
genetic testing and colonoscopy, benefits are received later in time. Both these 
technologies will impact significantly on the consumption of resources. It is imperative, 
therefore, for decision-makers to assess the benefits and costs of genetic and screening 
technology; and be able to compare these benefits and costs to various other options 
(Grosse et al. 2008; Buchanan et al. 2013). Economic evaluations are systematic analysis 
of relevant healthcare alternatives in order to compare both costs and consequences of 
alternative options with the intention of informing on a preferred course of action 
(Drummond et al. 2005). Economic evaluations commonly encountered in healthcare 
include cost-effectiveness analysis (CEA), cost-utility analysis (CUA) and cost-benefit 
analysis (CBA). A CEA compares cost and consequences (effectiveness) of different 
alternatives and generally, only one outcome is considered per cost incurred. Outcomes for 
CEA are measured in natural units (e.g. blood pressure – mmHg). A CUA compares costs 
and consequences in terms of patient utility (e.g. quality adjusted life year – QUALY) and 
more than one outcome may be considered for the patient (Drummond et al. 2005). The 
limitation of performing a CUA for genetic testing is that, generally, QUALYs (utilities) 
are calculated directly for the affected individual. The extended effect (benefit or harm) to 
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family members in terms of knowledge for informed decision-making are often excluded 
and would require specific modelling in order to be considered. Cost-benefit analysis 
(CBA) considers costs and a broad range of different patient outcomes. In a CBA both 
costs and outcomes are valued in monetary terms (Drummond et al. 2005). CBAs take into 
consideration both health and non-health outcomes, and my not be useful if a decision-
maker only wants to focus on optimising health outcomes (Grosse et al. 2008). 
Partial economic analysis allow for important intermediate stages of understanding the 
costs and consequences of alternative healthcare programmes (Drummond et al. 2005; 
Gray et al. 2012). In this study, a partial economic evaluation will be performed that 
focuses on costs i.e. collecting primary data to determine the cost of providing 
colonoscopy and germline tests for patients with Lynch Syndrome and their relatives. The 
reason for collecting primary cost data is that even with attempts to standardise costing 
methodologies, availability of financial data and financial practices impact on results and 
therefore, data is very much time, context and country specific. Furthermore, estimating 
costs from medical charges may not produce accurate results as charges may be influenced 
by factors such as service provider monopolies, cross-subsidisations, profit generation or 
negotiated contracts (Drummond et al 2005; Gray et al. 2012). 
Table 2 reflects the costs reported in various cost-effectiveness studies performed in 
different countries (Gross 2015). Total screening costs were around $2 242 to $3 345. One 
study was unusually high at a total cost of $6 312. Generally, the largest contributors 
towards the screening costs were the genetic testing for MLH1 and colonoscopy. Long-
term the colonoscopy cost will be the main cost driver as the other costs are once-off costs. 
The lowest cost contributors were the genetic counselling costs and approaching relatives. 
The predictive tests for relatives were in all cases significantly lower than the genetic 
sequencing for MLH1 (identifying the mutation). This indicates the value of identifying a 
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family mutation – i.e. relatives may be identified at a much lower cost and may benefit 
more from colonoscopy screening as they may not have cancer yet as opposed to the 
proband who often present with cancer already. 
Table 2: Base case estimates of costs of routine testing and colonoscopy for Lynch 








































































































































Mvundura et al. 
(2010) USA 
22 106 194 290 899 350 61 441 1043 3345 
% of total cost 0.66 3.17 5.80 8.67 26.88 10.46 1.82 13.18 31.18 100 
Ladabaum et al 
(2011) USA 
NR 112 198 300 942 118 492 610 690 2970 
% of total cost NR 3.77 6.67 10.10 31.72 3.97 16.57 20.54 23.23 100 
Sie et al (2007) 
Netherlands 
25 136 0 184 1184 77 353 430 206 2242 
% of total cost 1.12 6.07 0 8.21 52.81 3.43 15.74 19.18 9.19 100 
Snowsill et al 
(2014; 2015) UK 
0 0 103 366 714 103 265 368 911 2565 
% of total cost 0 0 4.02 14.27 27.84 4.02 10.33 14.35 35.52 100 
Severin et al 
(2014) Germany 
57 161 0 166 5268# 57 281 338 265 6312 
% of total cost 0.90 2.55 0 2.63 83.46 0.90 4.45 5.35 4.20 100 
Barzi et al (2015) 
USA 
NR 112 198 300 942 118 492 610 690 2970 
% of total cost NR 3.77 6.67 10.10 31.72 3.97 16.57 20.54 23.23 100 
NR: Not reported  * Not added to total (included in combined counselling and test)    
# Genetic testing costs is not higher in Germany. The German reimbursement for gene sequencing is an outlier.  
    
Adapted from Grosse 2015. Healthcare. 3, 860-878. 
The perspective and target audience assumed in an economic analysis are significant as 
these inform on the costs and other considerations that will be included in the analysis 
(Drummond et al. 2005; Grosse et al. 2008). Most economic analyses are performed from 
the provider perspective; however a more societal approach may be more appropriate for 
genomics due to its indirect impacts (Buchanan et al 2013).  Furthermore, health 
practitioners place significant value on informed decision-making by the patient, whereas 
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for health care payers this may not be relevant (Buchanan et al 2013). For this study, 
however, a health provider perspective will be applied as the aim of the study is to estimate 
and compare the cost of colonoscopy screening as a step towards assessing affordability.  
In this case, the key target audiences will be the service providers, policy makers, 
government and researches. 
Costs may be determined by stochastic analysis i.e. understanding that the resources 
required may vary from patient to patient due to known and unknown variables, and 
therefore cannot be predicted accurately (Gray et al. 2012). In this case, in practice, the 
variations between patients may be considerable. In a deterministic analysis, a model 
treatment is assumed per patient and costed. (Gray et al. 2012). Germline testing for 
identifying the responsible MMR gene mutation may have significant variation in cost 
between patients as the number of tests required to identify the gene mutation vary from 
patient to patient (Buchanan et al. 2013). In many cases, genetic testing has a research arm 
associated with it which impacts on testing procedures applied. For LS, national standard 
protocols for genetic testing are not established and practices may vary from laboratory to 
laboratory. The timing of collecting costs is also important as standard practices for 
genomic interventions evolves over time and different techniques have different 
sensitivities and specificities (Buchanan et al. 2013). To overcome these challenges, and as 
recommended by Grosse et al. (2008) costs should, therefore, be based on actual utilization 
data and processes followed at GSH and UCT. Additionally, analysis of data should be 
restricted to a specific period to ensure that the latest technologies used at GSH / UCT 
were considered only.  
Three stages are generally involved in performing a cost analysis i.e. (i) identifying 
resources required, (ii) measuring / quantifying these resources using physical units and 
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(iii) valuing these resources (Drummond et al. 2005; Gray et al. 2012; Mangham 2009). 
Two approaches are commonly used for identifying resources; namely, gross-costing 
(referred to as top-down costing) and micro-costing (referred to as bottom-up costing) 
(Drummond et al. 2005; Gray et al. 2012). Gross-costing identifies costs in bundles e.g. 
cost of a day in hospital, whereas micro-costing involves identifying and costing all 
activities, consumables, staff, etc. related to the day in hospital. The approach used will 
depend on the ease of collecting the data and the resources-use difference between the 
comparisons (Gray et al. 2012). Since very little costing data and bundle costs estimates 
are available on colonoscopy and germline testing in the public sector, a predominantly 
micro-costing approach is more appropriate. Measurement of resource quantities may be 
collected by observation, patient or staff interviews, completing questionnaires or folder 
reviews. Valuing of resources should, ideally, reflect opportunity costs. In practice, market 
prices are assumed to be a reasonable approximation of opportunity costs (Drummond et 
al. 2005; Gray et al. 2012). Market prices, however, have an element of profit attached to it 
((Drummond et al. 2005; Gray et al. 2012) and in the public sector in South Africa, prices 
may differ significantly between private and public sector. In South Africa, the Uniform 
Patient Fees Schedule (UPFS) is used as a reference price list in the public sector to reflect 
State prices (Department of Health: Western Cape 2015). These prices for services are 
often approximations and not always based on actual costs (Personal communication: 
Kathrie-Salie, M: Directorate Finance: Department of Health - Western Cape). Thus, in 
our study, resources for services will be valued by collecting primary data rather than 
using reference lists, hospital charges or market prices. 
Costs are estimated in terms of capital costs and recurrent costs (Drummond et al. 2005; 
Gray et al. 2012). Capital costs are investments made at a single point in time and 
represent an investment in assets used over a period of time. The cost of a capital item is 
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associated with the lost opportunity of investing the capital expenditure for an alternative 
benefit. Most capital costs depreciate over time, while some, such as land and buildings 
maintains its value and are non-depreciable. The “equivalent annual cost” is determined by 
annuitizing the initial capital expenditure. Annuitizing takes into account opportunity cost, 
depreciation and the life-years of the capital item. Recommended discounting rates for 
annuitizing is 3%. Life-years of a capital item or equipment reflect the number of usable 
years of the item (Drummond et al. 2005; Gray et al. 2012).  – Buildings are usually 
allocated usable life-years of 30 to 50 years, equipment five to ten years, and furniture one 
to five years (Drummond et al. 2005; Gray et al. 2012; Mangham 2009; Somda 2007).  
Shared costs (e.g. overhead costs) may be allocated in a variety of ways, but are usually 
allocated based on the different activities that drive the departments e.g. paid hours for 
staff, square metres for housekeeping, etc. (Drummond et al. 2005; Gray et al. 2012). The 
unit used to determine the allocation of shared costs must be as homogenous as possible 
with regards to cost across services and must be associated with every patient concerned 
(Drummond et al. 2005; Gray et al. 2012). 
Total costs provide policy makers and service providers with information of total 
expenditure, budget requirements and affordability (Drummond et al. 2005; Gray et al. 
2012). Average unit cost data provide information, on average, of cost changes when data 
is generalised across different settings or patient utilisation patterns. Average unit cost may 
differ as it may include settings of different levels of production efficiency. Marginal costs 
provide information on the additional cost for every additional unit produced. This is 
important for scaling up of services (Drummond et al. 2005; Gray et al. 2012). In our 
study, average unit costs for colonoscopy and genetic testing will be estimated and this 
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will be used to calculate total costs based on patient utilisation and expected utilisation 
patterns. 
Programmes with differential timing of resource outlays need to accommodate for time 
preferences. Most people desire a positive time preference because of (i) opportunity costs, 
(ii) the value of an amount of money today is worth more than the value of the same 
amount of money in the future, and (iii) uncertainty of the future. The discount rate is 
based on a value judgement by society and reflects the extent to which society is willing to 
postpone their gratification for the benefit of the future generations. Future costs are, thus, 
discounted to present value. There is not yet consensus on the discount rate to use in 
economic evaluations. However, discount rates are published in many countries. Discount 
rates commonly reflected in literature is usually used in countries where discount rates are 
not published. As the discount rate is a subjective variable, sensitivity analysis on no 
discount rate and commonly published discount rates such as 3% or 5% are recommended. 
(Drummond et al, 2005; Department of Health: Government Gazette No. 36118). 
Sensitivity analysis is a method that is used to deal with uncertainty (Drummond et al. 
2005). Sensitivity analyses are based on uncertainties (parameters) reflected in literature or 
in our study; and inform on the extent to which these parameters will influence costs or 
outcomes (Drummond et al. 2005). According to literature, discount rates, adherence to 
colonoscopy and positivity rate of relatives are main parameters that influence colorectal 
screening costs in LS (Gross 2015). 
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9. Cost-effectiveness of screening strategies for Lynch Syndrome  
A number of cost-effectiveness studies on LS screening has been published (Snowsill et al 
2014; Grosse 2015). However, these studies focused on high income countries and 
generalisability to the South African context poses a challenge. 
A Health Technology Assessment (HTA) published in 2014 included a systematic review 
of 32 cost-effectiveness studies (Snowsill et al. 2014). Most of the studies were conducted 
in the United States of America and were designed from a health service provider 
perspective. The most frequently used test strategy could not be determined from the 
review as the studies employed different tests and combinations of tests. Furthermore, 
different studies made different assumptions and this complicated direct comparability of 
studies. The management strategies across the studies were fairly consistent and included 
biennial to annual colonoscopy screening from the age of 25 years, with extensive 
colorectal surgery on diagnosis of colorectal cancer. Many of the studies failed to comply 
with the Drummond checklist (Drummond et al. 2005).  The review could not inform on 
the consistency with regards to the strategies or individual test that would be most cost-
effective. All studies, however, concluded that screening for LS compared to no screening 
was cost-effective (Snowsill et al. 2014). Similar findings were found in a review by 
Grosse (2015) who also concluded that cost-effectiveness is subject to the alternative 
strategies available and the methods of collecting and valuing costs. He further suggested 
that in order to inform appropriately on cost-effectiveness for screening for LS, unlike 
most of these studies where a number of assumptions are applied, actual real-life clinical 
practice should be documented as costs, adherence to colonoscopy, number of relatives 
tested vary across populations (Gross 2008).    
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Snowsill et al. (2014) further conducted a health technology assessment comparing eight 
screening strategies. The more tests that were performed in sequence, the greater the costs 
as well as the specificity. Little, however, is reported in the literature regarding sensitivity 
and specificity when performing tests sequentially except for BRAF V600E test after IHC 
or MSI with MLH1. The HTA found that, compared to no testing as the base case, MSI + 
BRAF V600E + genetic testing produced the lowest ICER. Sensitivity analysis indicated 
that, even at low rates of acceptance of diagnostic tests and genetic counselling, LS testing 
was found to be cost-effective compared to no testing. Sensitivity analysis performed on 
widely varying the number of relatives per proband, including no relatives, found 
screening for LS more cost-effective than no screening. LS diagnosis and true LS status 
greatly influenced life expectancy. The total number of colonoscopies was influenced by 
the correct diagnosis of LS and adherence to screening. Strategies that increase the number 
of false positives and reduce the number of false negatives resulted in an increased number 
of colonoscopies and therefore increased costs. Strategies that identified more LS positive 
patients reduced the expected number of colorectal cancers for probands and relatives. 
This is due to the impact of colonoscopy screening as a preventative measure for colorectal 
cancer. Universal gene testing, therefore, resulted in the lowest number of colorectal 
cancer in both probands and relatives, but was the most expensive. Clinical outcomes were 
also strongly influenced by compliance with preventative measures. Higher number of 
colonoscopies produced less colorectal cancer and higher life expectancies. The majority 
of the diagnosing cost for the cohort was due to diagnosing the probands, as opposed to 
diagnosing the relatives. Costs were driven by the number of tests taken. Compared to 
long-term costs, diagnostic costs were small and did not influence the variation in costs 
between strategies. The most influential cost driver, long-term, was the cost of 
colonoscopies. During univariate sensitivity analysis, ICERS were nearly doubled or 
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halved when colonoscopy costs were doubled or halved, respectively. As QUALY’s 
increased, the total costs increased across the strategies as expected due to the preventative 
measures used. The time of diagnosis, the age at diagnosis, the stage at diagnosis and the 
site of the cancer, impacts on the management of colorectal cancer and this may vary 
substantially from patient to patient. It is, thus, an enormous task to estimate the cost of 
treating cancer and data cannot be easily generalised. However, in the HTA conducted in 
the United Kingdom, it was found that preventative costs outweighed the increased savings 
in cost from colorectal cancer treatment (Snowsill etl al. 2014). 
In summary, the number of colonoscopies was the main cost driver; and this was 
influenced by number of LS positive probands, adherence rate to colonoscopy and number 
of positive relatives that tested positive.  
 
10. Summary of literature review 
 
- Individuals with LS have a high risk for colorectal cancer and the onset of cancer 
occurs at ages when persons are economically active and support families. South 
African families with LS have been implicated with the MMR genes, MLH1 and 
MSH2, which presents the highest risks (40% to 70%) for colorectal cancer. 
- The literature showed a paucity of randomised control trials on the benefit of 
colonoscopy in colorectal cancer. However, observational studies provided 
acceptable evidence that colonoscopy screening is the only effective screening 
strategy for colorectal cancer in LS and reduced mortality and the incidence of 
colorectal cancer. 
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- Differential diagnosis of LS (family history, histology, computational model, etc.) 
lacks sensitivity and specificity to adequately identify LS individuals for 
colonoscopy screening. Genetic testing provides a definitive diagnosis for LS.  
- Standard protocols for genetic testing are complex and vary, and best practice 
guidelines have not been established. Costs of genetic testing may, therefore, differ 
significantly according to the series of tests performed, performance standards, 
laboratory protocols, costs of resources, etc. Generalisability of published data to 
varying settings is, therefore, challenging and often not possible. 
- Timing of an economic evaluation is critical as genetic testing technology evolve 
continuously. 
- Generally, genetic testing do not impact directly on health outcomes that are 
important for a service provider (e.g. mortality or morbidity), but inform on further 
management of a patient. Thus, it is important to include the costs of the both the 
genetic testing and the intervention (e.g. colonoscopy) in an economic analysis. 
- Cascade genetic testing i.e. testing of a relative is less costly than diagnosing a 
proband; and the benefit for the relative may be greater as he / she may not have 
cancer yet. Thus, cascade testing reflects the benefit of genetic testing and has to be 
considered when assessing costs and benefits.  
- Long-term, colonoscopies contribute to the majority of the costs of screening for 
colorectal cancer. Parameters that influence the number of colonoscopies in the 
screening process include discount rates, adherence to colonoscopy and positivity 
rate of relatives.  
- No published local study involved the economic aspects related to providing a 
colonoscopy screening service for Lynch Syndrome. 
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11. Conclusion 
An overview of the literature indicated that publications focused predominantly on high 
income countries which are not generalisable to South Africa. A number of evidence-based 
guidelines and one detailed health technology assessment provided best practice evidence 
as well as cost-effectiveness data. Though these publications provided guidance on 
recommended practices, practices in South Africa differ due to availability of resources, 
skills and equipment. Grosse et al. (2008) recommended that in order to inform 
appropriately on cost-effectiveness for screening for LS, unlike most of these studies 
where a number of assumptions are applied, actual real-life clinical practice should be 
documented. The aim of our study, therefore, is to estimate from actual expenditure and 
utilisation data, the costs of implementing screening options for colorectal cancer for 
patients with LS. 
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Aim: Individuals with Lynch Syndrome have a 25% to 75% lifetime risk of colorectal 
cancer and the cancer generally presents at an early age. It is, thus, important to establish 
the cost of strategies to prevent or delay the onset of cancer. Colonoscopy was the only 
screening method shown to be effective. This study compared the cost of two screening 
approaches - colonoscopy only (Strategy 1) versus genetic testing for Lynch Syndrome 
followed by colonoscopy for the individuals that tested positive (Strategy 2).  
Method: A comparative cost analysis of two screening approaches was conducted from the 
health service perspective at a tertiary hospital. Probands that were selected for genetic 
testing between 01 November 2014 and 30 October 2015, and their relatives were 
analysed. From this cohort, all probands and their 1st degree relatives were analysed 
according to Strategy 1. From the same cohort, probands that tested positive for a mutation 
and their 1st degree relatives were analysed according to Strategy 2. Total costs for the two 
screening strategies were estimated and compared. Sensitivity analyses were performed on 
adherence rates to colonoscopy, positivity rates of relatives and discount rates. 
Results: A total of 40 families were studied. The total cost for Strategy 1 amounted to 
R4 932 718 ($332 617) compared to R390 308 ($26 319) for Strategy 2 (Discount rate 3%; 
Adherence 75% and Positivity rate of relatives 45%). Base case analysis indicated a 
difference of 90% less in the total cost for Strategy 2 compared to Strategy 1. One-way 
sensitivity analyses showed that the difference in cost between the two strategies was not 
sensitive to changes in discount rates, adherence rates or positivity rates of relatives.   
Conclusion: Colonoscopy screening for Lynch Syndrome and at-risk patients was 
substantially less costly when combined with genetic testing. Effectiveness of the 
screening programmes should be established through further research. 
Key words: genetic testing, Lynch Syndrome, HNPCC, colorectal cancer, colonoscopy, cost-effectivenss 
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In South Africa, colorectal cancer is the fifth most common cancer, with approximately 4 
697 new cases and 3 138 deaths reported in 2012 (National Health Laboratory Services: 
Globocan, 2015). Just over half of the new cases diagnosed and 41% of deaths occurred in 
individuals younger than 65 years of age (National Health Laboratory Services: Globocan, 
2015). The most common cause of hereditary colorectal cancer is Lynch Syndrome (LS) 
which accounts for approximately 3% to 5% of all colorectal cancers (Graham et al. 2012; 
Bonadona et al. 2011; Snowsill et al. 2014). 
LS is clinically defined as a disorder that predisposes individuals to colorectal cancer, 
endometrial cancer and certain other cancers as a result of an underlying germline 
mismatch repair (MMR) gene mutation (Vasen et al. 2013). The disorder presents with 
high rates of multiple primary tumours, has an early age of onset and generally has an 
absence of typical risk factors (Vasen et al. 2013). Carriers of a mutation in any of the 
MMR genes have a lifetime risk for colorectal cancer of 25% to 75%, compared to a 5% 
lifetime risk in the general population (Cohen et al 2014; Giardiello et al. 2014; Snowsill et 
al. 2014; Vasen et al 2013). The highest risks, in the region of 40% to 70%, are associated 
with individuals with MLH1 and MSH2 mutations, with lower risks reported for MSH6 
(10% - 22%) and PMS2 (15% - 22%) (Bonadona et al. 2011; Steinke et al. 2013; Vasen et 
al. 2013; Giardiello et al. 2014). LS-associated mutations have an autosomal dominant 
pattern i.e. if a parent carries the mutation then there is a 50% chance that the mutation will 
be passed on to the child (Snowsill et al. 2014). 
Colorectal cancer is the most common cancer associated with LS (Snowsill et al. 2014; 
Vasen et al. 2013). Progression of adenoma to carcinoma is approximately five times more 
accelerated in individuals with LS compared to sporadic and familial colorectal cancers. 
Furthermore, colorectal cancer is generally asymptomatic until it has reached an advanced 
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stage (Snowsill et al. 2014; Vasen et al. 2013). As colorectal cancer has a relatively earlier 
onset in LS individuals than occurs in sporadic forms (Bonadona et al. 2011; Cohen, et al. 
2014; Snowsill 2014), persons affected are usually economically active and support 
families. Thus, preventing or delaying cancer onset, would have social as well as economic 
benefits. An effective screening programme is fundamental for early detection and 
successful management of colorectal cancer (Snowsill et al. 2014; Vasen et al. 2013). 
Advantages of appropriate screening are the early detection of cancer and consequently 
improved chances of curative treatment; and the early detection of pre-cancerous lesions 
which allows for removal of the polyps before they can progress to cancer (EGAPP 2009; 
Giardello et al 2014). Colonoscopy is the only screening method that has proved to be 
effective for these individuals (Snowsill et al. 2014; Vasen et al. 2013). Studies conducted 
in high income countries have shown that effective colonoscopy screening programmes 
reduced mortality by 62% to 72% (Palomaki et al. 2009; Giardiello et al. 2014; Snowsill et 
al 2014). Stupart et al. (2009) showed an 80% decrease in mortality in a South African 
study, based on the communities which are the subjects of the present study. For the 
general population colonoscopy screening every five to ten years is recommended for 
individuals commencing from around 50 years old (Palomaki et al. 2009; Giardiello et al. 
2014; Snowsill et al 2014). However, for LS-affected and at risk individuals biennial 
colonoscopy is recommended for persons from as young as 25 years old and annual 
colonoscopy is recommended for persons from 30 years to around 70 years old (Palomaki 
et al. 2009; Giardiello et al. 2014; Snowsill et al 2014).  
In a resource-constrained environment, accurate prediction of individuals at high risk of 
colorectal cancer who will benefit from colonoscopy is intuitively desirable.  Effective 
prediction will leave those at low risk of disease unexposed to the hazards of potentially 
invasive screening procedures, as well as optimise the use of scarce resources such as 
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equipment and skilled staff. Genetic testing to diagnose LS allows for identification of 
individuals at high risk of colorectal cancer (Snowsill et al. 2014).  
The lack of genetic testing for LS and colonoscopy screening programmes in South Africa 
pose a major drawback for the management of colorectal cancer in individuals with LS. 
Also, unlike index screening colonoscopy, with genetic testing it is possible to determine if 
a patient has LS (Giardiello et al. 2014; Snowsill et al 2014). We, thus, hypothesised that 
genetic testing with colonoscopy screening will reduce the need for intensive colonoscopy 
on a large number of patients and consequently, reduce the cost of screening. Furthermore, 
determining the costs of these services is a key initial step to assessing affordability and 
successful implementation of such services. Thus far, no published study has assessed the 
cost implications of colonoscopy and genetic testing screening service for patients with LS 
in South Africa. Grosse et al. (2008) recommended that in order to inform appropriately on 
cost-effectiveness for screening for LS, actual real-life clinical practice should be 
documented. Published studies (Snowsill et al 2014; Grosse 2015) indicated that long-
term, colonoscopy costs were the biggest cost drivers. Preventative measures 
(colonoscopy) exceeded the cost savings from the delayed management of cancer. In terms 
of genetic testing, costs for diagnosing a proband exceeded the cost for diagnosing a 
relative. Adherence to colonoscopy, uptake of genetic testing and positivity rates of 
relatives are the key parameters that influence total costs of colonoscopy programmes 
(Snowsill et al 2014; Grosse 2015).  
This study estimated and compared the cost of two screening approaches – intensive 
colonoscopy only for individuals considered at an increased risk of LS (e.g. probands or 
their first degree relatives) versus genetic testing for LS of at risk individuals followed by 
intensive colonoscopy only for the individuals who tested positive.  
  
5 




2.1 Study design and objectives 
 
A comparative cost analysis from the health service perspective, using a micro-costing and 
ingredients-based approach was conducted. Costs were collected in 2015 and presented in 
the 2016 South African Rands and US Dollars. The unit costs for genetic testing and 
colonoscopy were estimated; and the total number of colonoscopies required for each 
strategy was projected. This information was utilised to estimate and compare the total cost 
for the two strategies. 
2.2 Screening strategies 
 
Two screening strategies for colorectal cancer were considered, based on what is currently 
available at GSH and the research interface with the Human Genetics Research Unit in the 
Division of Human Genetics at UCT. Both strategies were applied to the same study cohort 
and costed. Strategy 1 involved intensive colonoscopy screening for all patients with 
colorectal cancer who were suspected of having LS based on the Revised Bethesda 
Criteria, as well as their 1st degree relatives. Strategy 2 involved intensive colonoscopy 
screening only for probands and 1st degree relatives with a genetic test-confirmed diagnosis 
of LS. Individuals who were negative on germline testing were managed as per the general 
population i.e. colonoscopy every 10 years from the age of 50 years. Intensive colonoscopy 
screening involved biennial colonoscopy for patients under 30 years of age, and annual 
colonoscopy for individuals aged 30-60 years. Individuals older than 60 years were 
managed as per the general population i.e. colonoscopy every 10 years (Voster, A: 
Division of Human Genetics: UCT, personal communication 2015). 
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2.3 Setting and population 
 
The study was undertaken at Groote Schuur hospital, a public sector tertiary hospital in 
Observatory in Cape Town that provides sub-specialist care. In South Africa, 
approximately 80% of the population seeks health care in the public sector (Department of 
Health, 2014). The study included individuals from the Western Cape and Northern Cape 
provinces. Subjects were recruited from the DNA and pedigree database (Ethics approval: 
HREC REF: 217/2010) in the Division of Human Genetics at the University of Cape Town 
(UCT). 
In this study, a proband is defined as the first medically identified individual in a family 
affected with a disorder and serves as the starting position for the genetic study of the 
family.  Probands captured on the database were selected according to the Revised 
Bethesda Criteria after presenting with colorectal cancer or other LS-associated cancer; 
and may or may not have LS (Voster, A: Division of Human Genetics: UCT, personal 
communication 2015). As genetic testing is evolving and becoming more affordable or 
available, different test strategies have been applied over the years. To ensure that the latest 
available genetic procedures / tests employed were used to estimate costs, analysis of data 
was limited to probands tested between 01 November 2014 and 31 October 2015.  A total 
of 40 probands and 934 relatives (40 families) on the DNA database were analysed 
according to patient demographics and screening strategy 1 and 2 i.e. the two screening 
options were applied to the same 40 families and costed (For details of the analysis - see 
Part D: Appendices: S1 and S2 Figs). From the 40 families, only probands and their first 
degree relatives (FDRs) were identified to receive colonoscopy screening as per the two 
screening strategies. FDRs are parents, children or siblings of the proband. FDRs of LS 
positive individuals have a 50% chance of having the LS-mutation (Snowsill et al. 2014) 
and were thus selected as high risk. Furthermore, individuals <25 years, >60 years, 
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deceased, spouses and family of spouses were excluded as they would not be eligible for 
colonoscopy screening. For Strategy 2, individuals were also assessed according to the 
genetic test results and only LS-positive individuals were assessed in terms costs for 
Strategy 2. The genetic tests performed and the results thereof are illustrated in Part D: 
Appendices: S3 Fig. Test results were derived from the National Health Laboratory 
Services (NHLS) and the DNA database. Surgical procedures performed were obtained 
from patient medical records. Five patients that had total colectomies were excluded as 
their screening procedures would not be done by colonoscopy. The number of 
colonoscopies required per proband and per FDR up to the age of 70 years was projected 
per screening strategy, taking into account the actual age of the individual.  
In summary, for strategy 1, a total of 146 individuals were identified as eligible for 
colonoscopy. The total number of colonoscopies per lifetime for the eligible individuals for 
Strategy 1 was estimated as 2 671. For strategy 2, all 40 probands received genetic testing 
and only LS-positive probands and their families were further analysed for eligibility for 
colonoscopy. Thus, for strategy 2, a total of 12 individuals were identified as eligible for 
colonoscopy and a total of 264 colonoscopies were estimated for the lifetime for these 
individuals.  
2.4 Colonoscopy 
Colonoscopy is a 30 to 60 minutes procedure performed in a dedicated, equipped room 
(Algar, U: Surgical Gastroenterology Unit: GSH, personal communication 2015). A 
colonoscope is inserted into the rectum, through the colon and as far as the caecum. Prior 
to the procedure, patients are given a special cleansing preparation to clear the bowel. 
Sedatives may be given for pain control and to relax the patient. An intravenous cannula is 
prepared in the event that patients may require intravenous fluid or medication. The 
patient’s heart rhythm and blood pressure is monitored continuously. Post-colonoscopy, 
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the patient is kept in an observation area for one to two hours (Algar, U: Surgical 
Gastroenterology Unit: GSH, personal communication 2015). 
2.5 Genetic testing procedures 
The reflex genetic testing procedure followed by the Division of Human Genetics at UCT 
for diagnosing LS was applied in this study. A database of all colorectal patients operated 
on at GSH is maintained and any patient meeting the Revised Bethesda Criteria underwent 
genetic testing (Voster, A: Division of Human Genetics: UCT, personal communication 
2015; Coetzee 2013). Where possible, Immunohistochemistry (IHC) testing was used 
routinely as a first line preliminary screening test. Negative staining for a specific gene on 
IHC testing suggested a mutation affecting the respective gene and an increased risk for 
LS. If the IHC showed presence of all genes, but a strong clinical suspicion existed (e.g. 
family history, or relatively young age at diagnosis), the patient would be offered 
Microsatellite Instability (MSI) testing. MSI testing was only provided on request as it is 
relatively expensive, labour intensive, and requires a skilled geneticist. IHC and MSI were 
provided by the NHLS. Germline testing was provided by NHLS and the Division of 
Human Genetics, UCT. Genetic testing encompassed DNA extraction from whole blood 
following venepuncture, followed by testing for the five common founder mutations, i.e. 
mutations known to affect large family communities in our environment. The founder 
mutations were resolved by:  
(i) A polymerase chain reaction (PCR), amplifying the fragment of DNA carrying the site 
of the mutation; followed by a restriction enzyme digest, which will specifically 
recognise the mutated DNA sequence and cut it.  The cut (mutation positive) and 
uncut (mutation negative) fragments are distinguishable on an agarose gel run in an 
electric field (Hedge et al 2013), or  
(ii) PCR followed by direct Sanger sequencing – which produces a graphic read out 
showing the exact site of the mutation (Hedge et al 2013), or 
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(iii) Multiplex Ligation-dependent Probe Amplification (MLPA) which detects 
deletions/insertions of whole exons of the respective gene(s) (Hedge et al 2013).  
Where a previously identified mutation that is not one of the founder mutations was 
suspected, Sanger sequencing was done and if positive, this was followed by another 
sequencing test on a separate day, and preferably on DNAs from a separate blood sample, 
for quality assurance purposes. Only on identification of the MMR gene mutation in the 
proband, would the at-risk relatives be offered genetic testing for the identified MMR 
mutation (predictive testing). BRAF V600E was not offered due to its technical 
complexity. A genetic counsellor provided counselling prior to and after genetic testing, as 
well as follow-up counselling with every colonoscopy performed. Informed consent was 
obtained prior to genetic testing (Voster, A: Division of Human Genetics: UCT, personal 
communication 2015; Coetzee, 2013). 
In summary, IHC was performed on probands with suitable colon tissue available for this 
test (22 individuals). All 40 probands received screening genetic tests i.e. the Common 
Founder test (39 individuals) or a Sequencing test for those with a known family mutation 
that was not a founder mutation (one individual). Only probands with LS-positive 
screening tests (4 individuals) received quality assurance / confirmatory tests i.e. digestive 
test and / or another sequencing test. See Part D: Appendices: S3 Fig for the flow diagram 
of tests performed.    
2.6 Cost analysis 
Capital, overhead and personnel costs were computed in order to estimate the costs for 
colonoscopy and genetic testing. The costs for performing colonoscopy and genetic testing 
were identified, quantified (measured) and then valued (Drummond et al 2005; Gray 
2012). (See Part D: Appendices: S1 Table to S4 Table for examples of allocation of costs). 
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The equivalent annual cost of capital items were estimated by annuitizing the initial capital 
expenditure using a discount rate of 3% (Drummond et al 2005; Glick et al. 2007; 
Mangham 2009). Annuitizing makes allowance for opportunity cost, depreciation and 
useful clinical life years of capital items. The following useful life-years were assumed - 
buildings: 30 years; major equipment: 5 to 10 years; furniture: 10 years; and small 
equipment: 1 – 5 years (Drummond et al 2005; Somda et al. 2007). For shared building 
areas, equipment and furniture, the proportion of total utility (e.g. proportion of 
colonoscopy patients or proportion of total time) was used to estimate costs. For the 
diagnostic laboratory equipment, an efficiency rate of 65% and 70% was applied. The 
NDOH/CSIR/DBSA Order of Magnitude Estimator for New Hospitals (Department of 
Health: National 2014) and architectural drawings (Department of Health: Public Works 
2015) were used to obtain costs for building spaces. Construction firms provided costs for 
a diagnostic laboratory. Equipment costs were obtained from medical suppliers. Furniture 
items were identified from asset registers (Feb 2016) and the costs were derived from 
government contracts and suppliers. An 8% mark-up was allocated for maintenance of 
equipment (Rademeyer: Deputy Director: WCGH Department of Public Works, personal 
communication 2015. Building and land maintenance costs were included in the Overhead 
and Maintenance category. 
The GSH Finance report (BAS report 2015/16) and the UCT Finance Department provided 
cost information for shared overheads such as electricity, laboratory costs, housekeeping, 
stationery, maintenance, etc. Proportions in terms of colonoscopy patients or floor space, 
as appropriate, were used to allocate shared overhead costs. Costs for managerial and 
administrative overheads were estimated from the GSH personnel report (PERSAL report 
2015) and government salary packages (COLA: Appendix B to DPSA Circular 1 of 2015); 
and were allocated according to the proportion of GSH staff involved in colonoscopy. 
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For personnel costs, a unit cost (cost per minute) was determined by dividing the annual 
total cost to company (CTC) by the annual total working minutes of the staff member. This 
unit cost was multiplied by the total time utilised by the staff member to perform the 
required task to obtain staff costs. GSH personnel report (PERSAL report Nov 2015), 
government salary packages (COLA: Appendix B to DPSA Circular 1 of 2015) UCT staff 
salaries (UCT Finance Department) were used to value staff costs.  
Shared consumables costs were allocated according to the proportion of ward patients who 
underwent colonoscopy, whereas consumables and pharmaceuticals that were not shared 
were valued in terms of the quantities used (Department of Health & Treasury Contract 
Circulars 2012 to 2017).  
The average unit cost for colonoscopy was estimated by dividing the total annual costs for 
colonoscopy by the number of colonoscopies performed per annum. 
Costs for genetic tests were obtained from the NHLS and certain genetic tests performed at 
UCT were calculated using the ingredients approach as noted above.  The cost of genetic 
testing varied amongst patients depending on the type of test and the number of tests 
conducted on the patient. Thus, the unit costs for genetic testing were estimated by 
calculating the weighted average cost for genetic testing where the weighting was applied 
according to the proportion of patients that required a particular test or series of tests. 
The estimation of costs was based on the assumptions that: 
- individuals undergoing colonoscopy screening have mortality rates as per the 
general population (Statistics South Africa 2015), as mortality rates for LS 
individuals in our cohort were not available at the time of the study. This may 
reflect an overestimation of costs - see section 6: Limitations; and  
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- all persons selected for genetic testing would be willing to undergo genetic testing.  
To compare programmes with differential timing of resource outlays, time preference 
needs to be considered as positive time preference is desirable because of opportunity 
costs; value of a dollar today versus the future, and uncertainty of the future. Thus, a 
discounting rate of 3% was applied to discount future costs to present value (Drummond et 
al, 2005). As major adverse events are rare and literature indicated that costs are not 
significantly affected by including or excluding major adverse events, (Palomaki et al. 
2009; Grosse 2015), these were excluded from the study.  
 
2.7 Sensitivity analysis  
Uncertainties most relevant to the study included positivity rates of the predictive tests for 
relatives, adherence rates to colonoscopy and discounting rates. Based on literature, a 
discounting rate of 3% and an adherence rate of 75% were assumed for the base case in 
Strategy 1 (Drummond et al 2005; Grosse, 2015). According to the DNA database, 27% of 
relatives tested positive in 2015. However, literature indicated positive test rates of 39% to 
50% in studies carried out in high income countries (Grosse, 2015). Sensitivity analysis 
was, therefore, performed on positivity rates of 30%, 45% and 50%.  Adherence rates 
reported in studies ranged generally from 79% to 88% (Grosse, 2015). However, in a study 
conducted in South Africa for LS-diagnosed persons, adherence rates as low as 25% was 
reported (Bruwer et al, 2013). Thus, adherence rates of 85%, 75%, 50% and 25% were 
analysed. As discount rates applied are according to societal value judgements, and 
therefore subjective, Drummond et al (2005) recommended that sensitivity analysis be 
performed on discount rates employed commonly in literature. The Department of Health 
guidelines recommends a discount rate of 5% and requires that costs should also be 
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presented undiscounted (Department of Health; Government Gazette No. 36118). Hence, 
discount rates of 0% and 5% were used for the sensitivity analysis.   
Approval was obtained from the University of Cape Town Human Research Ethics 
Committee (HREC REF: 781/2015) and the relevant Provincial Department of Health 
authorities. The study was self-funded and was conducted as part of the requirements to 
complete the degree for a Master in Public Health: Health Economics at UCT. 
 
3. Results 
Analysis of 40 probands and 934 relatives resulted in 146 individuals and 2 706 
colonoscopies identified as per Strategy 1 and 12 individuals and 267 colonoscopies as per 
Strategy 2. Accommodating for the general population mortality rate, 2 671 colonoscopies 
were estimated for Strategy 1 and 264 colonoscopies were estimated for Strategy 2. The 
average age of persons in Strategy 1 and 2 were 38 years and 39 years, respectively. Just 
over 83% of persons in Strategy 1 and 100% in Strategy 2 required annual colonoscopy 
screening. For Strategy 1, the number of FDRs per proband was 2.93 and for Strategy 2, 
the number of FDRs per LS-positive individual was 2.75. 
 
3.1 Cost Analysis 
Table 1 shows the breakdown by category of costs for colonoscopy. Around 82% of the 
colonoscopy costs constituted staff (56%) and equipment (26%) costs. The rest of the costs 
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Table 1: Annual and unit cost by category for colonoscopy presented in 2016 Rand and US $ 
CATEGORY OF COST 
ANNUAL COST (n =2347) UNIT COST 
% OF TOTAL 
COST Rand US $ Rand US $ 
Staff   4 464 949.62   301 075.50   1 902.41   128.28  56.05% 
Equipment  2 106 100.49  142 016.22    897.36    60.51  26.44% 
Building (Construction)   280 419.00   18 908.90    119.48     8.06  3.74% 
Consumables   275 891.06   18 603.58   117.55     7.93  3.46% 
Overheads & Housekeeping  273 704.01  18 456.10    116.62     7.86  3.44% 
Laboratories  232 029.87   15 645.98   98.86   6.67  2.91% 
Hospital Admin Services  162 109.41  10 931.18   69.07   4.66  2.03% 
Pharmaceuticals  79 701.31  5 374.33    33.96   2.29  1.00% 
Laundry & Linen Services  53 175.99   3 585.70   22.66   1.53  0.67% 
Furniture Colonoscopy 13 913.84   938.22     5.93   0.40  0.17% 
Furniture Shared  6 927.06  467.10     2.95  0.20  0.09% 
 
TOTAL 7 966 400.18  537 181.40   3 394.29   228.88  100.00% 
Follow-Up Genetic Counselling  
(Applicable to Strategy 2 only) ---- ----  89.80  6.06  2.73% 
TOTAL 7 966 400.18  
 
 3 484.09   234.94  100.00% 
 
Table 2 presents the genetic counselling costs. About 69% of the genetic counselling costs 
were due to the initial outlay for genetic testing, while 31% of the costs were due to the 
follow-up counselling over the lifetime colonoscopy screening period.  
 
Table 2: Costs of genetic counselling for diagnosing Lynch Syndrome for probands and their 1st degree 









TOTAL COST % OF 
TOTAL 
COST Rand US $ Rand US $ 
ONCE-OFF GENETIC COUNSELLING SESSIONS FOR DIAGNOSING LS  
#Average cost of 
counselling of proband(s)   579.21   39.07  40  23 168.40   1 562.27  58.92% 
 #Average cost of 
counselling of relative(s)   373.49   25.18  11  4 108.39   277.03  10.45% 
FOLLOW-UP GENETIC COUNSELLING SESSIONS WITH COLONOSCOPY SCREENING PROCEDURE 
*Follow-up (F/U) 
Counselling  89.90    6.06 **80 to 134 
 7 192.00  
to 12 046.60  
 484.96  
to 812.31  30.63% 
TOTAL COST OF 
GENETIC COUNSELLING  
 
-------- --------- 34 468.79  
to 39 323.39 
 2 324.26  
to 2 651.61  100.00% 
#includes pre- and post-test counselling, pedigree documentation and referral 
*Assumption – 30% to 50% of relatives tested positive    
 
A total of 22 patients had three IHC tests performed per individual i.e. for MLH1, MSH2 
and MSH6 at a cost of R385 ($25) per test. Thus,  a total of 66 IHC tests were performed 
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which amounted to R25 401 ($1 712). No MSI testing was done on any of the patients in 
the cohort.   
 
The costs for genetic testing for diagnosing probands and their FDRs are shown in Table 3. 
Common founder mutation tests (screening) were performed on 39 probands. Restriction 
enzyme digest tests and sequencing tests (quality assurance) were performed on the three 
patients that tested positive with the common founder test. One proband with a suspicion 
of a known mutation that was not a founder mutation was diagnosed using sequencing 
testing for both screening and confirmatory purposes. The total costs for diagnosing all 
probands amounted to R107 940 ($7 279). Of this cost, 92% was due to the common 
founder mutation test cost. The weighted average unit cost per proband for confirming 
diagnosis of LS was R2 698 ($182) whereas the cost to test a relative for a known mutation 
was R926.12 ($62.45). 
 
Table 3: Cost of genetic testing for diagnosing Lynch Syndrome in probands and their 1st degree 
relatives presented in 2016 Rand and US $.  
 
A summary of the total costs for conducting genetic testing for the study cohort is shown in 
Table 4. About 78% (63% for genetic testing + 15% for IHC) of the genetic testing costs 
were attributable to the tests to diagnose the proband. The predictive testing for the 1st 
degree relatives only contributed 6% to the total genetic testing costs. The total cost of 
GENETIC TESTS COST PER TEST NUMBER 
OF TESTS 
       TOTAL COST 
Rand US $ Rand US $ 
DIAGNOSING LYNCH SYNDROME IN PROBANDS (n=40)                                                   
Common Founder Mutation 2 534.54  170.91 39  98 847.06  6 665.34  
Digest/Predictive  926.12  62.45 3   2 778.36  187.35  
Sequencing  1 263.04  85.17 5  6 315.20   425.84  
TOTAL   47 107 940.62   7 278.53 
WEIGHTED AVERAGE UNIT COST  
to diagnose a proband 2 698.52 181.96  
 
  
DIAGNOSING LYNCH SYNDROME IN 1st  DEGREE RELATIVES (n=11) 
Digest/Predictive  926.12  62.45 11  10 187.32 686.94 
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R170 805 ($11 517) was the once-off outlay to identify four LS patients and 11 FDRs in 
this cohort. This cost was constant for all scenarios with different parameters in Strategy 2. 
 
Table 4: Costs by category of genetic testing procedure for diagnosing LS in probands tested between 





UNIT COST TOTAL  COST % OF 
TOTAL 
COST Rand US $ Rand US $ 
IHC (Preliminary test) 66 384.86  25.95 25 400.76  1 712.80 14.87% 
Ddiagnosing LS in probands 40 2 698.52  181.96 107 940.62  7 278.53 63.20% 
Diagnosing LS in relatives 11 926.12  62.45 10 187.32  686.94 5.96% 
Counselling (Excl F/U Counselling) *112 sessions 4.49/min  0.30/min 27 276.79 1 862.00 15.97% 
TOTAL -----  -----  170 805.49  11 517.56 100.00% 
*Sessions ranged from 15 minutes to 90 minutes (112 sessions = 6075mins) 
 
Costs for the two screening strategies are reflected in table 5. The average unit cost for the 
entire genetic testing process to diagnose a proband (IHC, genetic testing, counselling) was 
estimated as R3 913 ($264). The average unit cost for the entire genetic testing process for 
diagnosing an FDR (genetic testing and counselling) was estimated as R1 300 ($88). The 
total cost for Strategy 2 was 92% less than the total cost for Strategy 1, i.e. R 390 308 
($26 318) at discount rate 3% and adherence 75% compared to R4 932 718 ($332 617) at 
discount rate 3%, adherence rate 75% and positivity rate of relatives 45%. 


















*Assumptions: Strategy 1 - Discount rate 3%; Adherence rate 75%;   Strategy 2 - Discount rate 3%; Adherence rate 75%, Positivity rate 
of relatives 45% 
CATEGORY OF 
COST UNIT COST QTY 
TOTAL COST  
STRATEGY 1 STRATEGY 2 
 Rand US $  Rand US $ Rand US $ 
Colonoscopy 3 394.29   228.88  2 671 9 066 148.59 611 338.41 -- 
 
 














        
Genetic testing cost 
- proband 
3 912.74   263.84  40 --  156 509.60 10 553.58 
 
Genetic testing cost 
- relatives 
 
1 299.61  
   











    








*TOTAL COST + 
ASSUMPTIONS 
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3.2 Base Case Analysis  
According to scenarios reported in literature, the base case was defined as colonoscopy 
screening only (Strategy 1) with an adherence rate of 75% and a discount rate of 3% 
(Snowsill et al 2014; Grosse 2015). The total cost for the base case amounted to 
R4 932 718 ($332 618). The base case was compared with all combinations of the 
following parameters: discount rates of 0%, 3%, and 5%; adherence rates of 25%, 50%, 
75% and 85%; and positivity rates of relatives of 30%, 45% and 50% (see Part D: 
Appendices S5 Table). Irrespective of the combination of parameters applied to Strategy 2, 
the costs for Strategy 2 remained between 89% and 96% less than the base case (Strategy 
1). Additionally, with the lowest adherence rate (25%) applied to Strategy 1 and the 
highest adherence rate 85% and positivity rate of relatives of 50% applied to Strategy 2, 
Strategy 2 still remained less costly. 
 
3.3 Sensitivity Analysis 
One-way sensitivity analysis was conducted to assess the influence of the various 
parameters on the cost difference between the two screening options. Figure 1 depicts the 
adherence rates, discount rates and positivity rates of relatives on the difference in cost 
estimates from the base case. The differences in cost estimates between the two strategies 
were not significantly sensitive to any of the parameters applied. The cost difference for 
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Figure 1: Impact of discount rates, adherence rates and positivity rates of relatives on the cost 
difference between Strategy 1 and Strategy 2 
 
Difference in cost was measured against the base case. The base case is indicated as 0% on Figure 1. 
Discount rate analysis (Constant parameters: Adherence rate 75% & Positivity rate 45%)   
Adherence rate analysis (Constant parameters: Discount rate 3% & Positivity rate 45%)  





This study has produced evidence that, for potential LS individuals and manifesting-LS 
individuals, colonoscopy screening with genetic testing (Strategy 2) is substantially less 
costly than offering colonoscopy screening only (Strategy 1). The total cost for Strategy 2 
was 92% less than the total cost for Strategy 1, i.e. R390 308 ($26 319) compared to 
R4 932 718 ($332 617). The base case analysis and one-way sensitivity analysis showed 
that this vast cost difference between Strategy 1 and 2 was not influenced by changes in 
discount rates, adherence rates and positivity rates of relatives. Strategy 2 also allows for 
high risk individuals to be identified to receive colonoscopy and thus, resources would be 
focused appropriately. In addition, low risk individuals would not be exposed to hazardous, 
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MLH1 and MSH2 mutations and the highest risks for cancer (40% to 70%), are associated 
with individuals with mutations in these two genes (Bonadona et al. 2011; Steinke et al. 
2013; Vasen et al. 2013; Giardiello et al. 2014).  
The Numbers Needed to Treat (NNT) for identifying a mutation in a proband was 10. 
Thus, to identify one patient it would cost R39 127 ($2 638) once off. We can translate this 
as R39 127 ($2 638) to exclude nine patients from the physical, psychological and 
financial implications of lifetime colonoscopy screening; while identifying the correct 
person who will benefit from colonoscopy. Furthermore, the cost of R39 127 ($2 638) for 
genetic testing would be offset easily by the savings incurred by not performing lifetime 
colonoscopies for nine patients. Similarly, the NNT for FDRs would range from 2 (50% 
positivity) to 3 (30% positivity). Thus, to identify one positive relative would cost between 
R2 600 ($175) to R3 900 ($262). This cost would exclude one in every two FDRs tested to 
one in every three FDRs tested from lifetime colonoscopy screening. Though the initial 
outlay to identify a mutation in a proband is high, the benefits for the relatives are acquired 
at a much lower cost. 
The common founder genetic test made up 91% of the costs of identifying a mutation in a 
proband and about 63% of the overall costs for the genetic testing procedure. Influencing 
the price of the common founder test would significantly influence the total cost of genetic 
testing. The number of colonoscopies was the cost driver in the screening process for 
Strategy 1 and this was influenced by adherence to colonoscopy screening. For Strategy 2, 
the cost driver(s) (genetic testing and / or number of colonoscopies) were influenced by 
adherence to colonoscopy as well as the proportion of relatives that tested positive. The 
total cost for genetic testing for the cohort was fixed at R170 805 ($11 518). At a mutation 
positive rate of relatives of 45% and an adherence of 75%, genetic testing contributed 44% 
and colonoscopy 56% to the total costs; whereas at a mutation positive rate of relatives of 
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30% and adherence of 25%, genetic testing contributed 78% and colonoscopy 22% to total 
costs. This shows that the fewer the colonoscopies, the greater the proportion of the cost 
for genetic testing. Genetic testing without colonoscopy screening provides no benefit in 
reducing the risk of colorectal cancer and therefore would be a waste of resources. Thus, 
the less colonoscopies performed, the greater the proportion of loss in benefit of the total 
cost. Uptake of colonoscopy screening amongst mutation carriers were reported as around 
79% to 88% in studies performed in high income countries (Grosse, 2015). However, a 
South African study reported adherence rates for LS-diagnosed persons of 25% over a 5 
year period (Bruwer et al., 2013). As access to colonoscopy screening in South Africa is 
generally limited to tertiary care hospitals in the public sector, this may be one of the 
reasons for the low adherence rate. A well-functioning, accessible colonoscopy programme 
is, therefore, important in order to optimise the benefits of genetic testing.  
Literature reported that the proportions of FDRs that tested positive for a mutation ranged 
from 39% to 50% (Grosse, 2015; Snowsill 2014). Also, family mutation prevalence in 
FDRs is assumed at 50% due to autosomal dominant inheritance of LS (Grosse, 2015). The 
proportion of relatives on the DNA database that tested positive for a mutation in 2015 was 
27%. This may be an under detection of mutations as the Division of Human Genetics: 
UCT test predominantly for founder mutations in MHL1 and MSH2 genes. Also, genetic 
testing in the public sector is not an established practice and many relatives may not have 
the opportunity to get tested. The greater the proportion of positive relatives identified to 
the proband, the greater the benefit of genetic testing as predictive testing is less expensive 
than diagnosing a proband and the relative is more likely to be ‘at risk’ (i.e. not affected by 
cancer yet). Thus, to improve the benefit / value for money of a genetic testing programme, 
testing of relatives should be strongly encouraged and facilitated. 
21 
PART C: Journal Article 
 
 
Staff executing colonoscopy contributed 56% to the total cost of colonoscopy. In the 
Western Cape colonoscopies are performed by sub-specialists and this significantly inflates 
the cost of colonoscopy. Furthermore, the demand for colonoscopy outweighs the supply 
of gastroenterologists. Data exists for non-physicians providing simple endoscopy 
procedures safely and effectively (Day et al, 2014); however, published data on non-
physician colonoscopy programmes is lacking (Ruco et al, 2016). This emphasises the 
importance of selecting appropriate persons for colonoscopy screening and avoiding 
unnecessary colonoscopies. An annual cost of R3 484 ($235) per patient for colonoscopy 
can be translated to about R290 ($20) per month to reduce the risk of colorectal cancer by 
62% to 72% (Palomaki et al. 2009; Giardiello et al. 2014; Snowsill et al 2014; Gross, 
2015). Compared with other tertiary treatments, this does not appear excessive. Conclusive 
evidence on whether colonoscopy screening every 1 to 2 years is superior to 2 to 3 years 
has not been established (Grosse, 2015; Vasen et al. 2013). Employing biennial 
colonoscopy would reduce the total cost of colonoscopies by almost half in both strategies 
as more than 80% of individuals in Strategy 1 and 100% individuals in Strategy 2 formed 
part of the annual colonoscopy regimen. 
Our study assumed that all persons identified for genetic testing would accede to testing. 
Based on this assumption, the number of FDRs tested per proband was 2.75 which is 
consistent with data reported in literature (Grosse 2015; Snowsill et al 2014). In addition, 
Bruwer et al. (2013) reported high uptake rates of 97% and 74% for siblings and children, 
respectively. Furthermore, predictive genetic testing of FDRs contributed only 6% to the 
total costs of genetic testing. Thus, the uptake for genetic testing would not significantly 
affect the total cost for Strategy 2.  
The cost of repeat colonoscopy, polypectomy, bleeding and biopsy was included in the 
cost estimate of colonoscopy. Major complications such as perforations are rare and were 
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excluded (Palomaki et al. 2009; Grosse 2015). Grosse (2015) reported that differences in 
assumptions regarding complications as well as excluding complications had little 




Colonoscopy screening for potential and confirmed LS patients were substantially less 
costly when combined with genetic testing. Implementing colonoscopy screening with 
genetic testing would, thus, support the efficient use of health care resources.  
 
6. Limitations 
There is potential for generalisability in the public sector across South Africa as practices, 
salary packages and procurement contracts are usually aligned.  However, patient profiles 
may differ. The study assumed general population mortality rates and did not include risks 
of other rarer cancers that are part of the LS spectrum and therefore the costs may be 
overestimated. This assumption is not expected to affect the direction of the results as the 
incidence of other cancers would be higher in the LS-diagnosed group (Strategy 2) and 
thus potential increased mortality rate in this group. Furthermore, in a cost-utility study 
Snowsill et al. (2015) reported that costs of surveillance of gynaecological cancer and other 
cancers associated with LS were excluded due to the lack of evidence of effectiveness of 
surveillance in these cancers (Snowsill et al., 2015). Strategies that included MSI testing, 
BRAF V600E and MLPA were not evaluated. At the time of the study, Sanger sequencing 
was less costly than MLPA and was the test used for quality assurance. As MSI was not 
requested for this cohort, the cost impact of MSI is assumed to be minimal as it would be 
once-off and required infrequently. The results of the genetic testing indicated that BRAF 
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V600E would not have been of value as all MHL1 genes had positive mutations. IHC 
testing identified mismatch repair mutations in MSH6 in 2 individuals and these patients 
tested negative for the common founder mutations (screening test). This study has 
provided evidence of cost implications for genetic testing and colonoscopy screening; 
however, further research on the effectiveness of such programmes would be of value. 
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1. SUPPLEMENTARY MATERIAL – COST ALLOCATIONS AND CALCULATIONS 
Examples of Allocation of Costs – MS Excel ® data collection and cost analysis tools 
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S3 Table: Example: Estimation of equipment cost for colonoscopy (or genetic test) 
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Apply 65% and 75% efficiency rate to genetic testing equipment. 
 



















Nuclease free H2O 1L        
100mM dNTP set        
Sense primer        
Antisense primer        
        
 
See Part A: Protocol – page 21 & 22 
See Part C: Journal Article – page 10  
2 
PART D: Appendices 




S1 Fig. illustrates the analysis for Strategy 1 of the probands and their relatives in terms of 
relationship, gender, age, etc. A total of 146 (14 +132) persons were selected for intensive 
colonoscopy.  
See part A: Protocol – Pages 14, 15 & 17 
See Part C: Journal Article – Page 7 
Demographic analysis per screening Strategy 1 of probands on the DNA database that were tested for LS between 
01 November 2014 and 30 October 2015, and their relatives
STRATEGY 1: COLONOSCOPY SCREENING FOR POTENTIAL LS INDIVIDUALS
41 patient (proband) samples received for unknown mutation
1 patient - duplication
Family size 40 probands / samples
Average:  974/40 = 24.35
Range:  78 (6 to 84)
Median: 25 974 patients plus relatives
Mode: 22
exclude deaths, spouses, 




25 - 29 years old Average eligible persons* per proband 30 - 60 years old
n = 36 242/40 = 6 n = 206
Proand 1° 2° 3° proband 1° 2° 3°
2 13 19 2 32 104 44 26
include proband & 1st degree relatives include proband & 1st degree relatives
exclude 1 x total colectomy patient exclude 4 x total colectomy patients
117/40 = 2.93
14 patients for intensive Average age = 38 years 132 patients for intensive 
colonoscopy screening colonoscopy screening
relatives in realtion to probands
S1 Fig:
Average first degree relative per proband
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S2 Fig. illustrates the analysis for Strategy 2 of the probands and their relatives in terms of 
relationship, gender, age, etc. A total of 12 persons were selected for intensive colonoscopy.  
See part A: Protocol – Pages 14, 15 & 17 
See Part C: Journal Article – page 7 
  
S2 Fig: Demographic analysis per screening Strategy 2 of probands on the DNA database that were tested for LS between 
01 November 2014 and 30 October 2015, and their relatives
STRATEGY 2: GENETIC TESTING FOR LS FOLLOWED BY COLONOSCOPY FOR LS POSITIVE INDIVIDUALS 
41 patient (proband) samples received for unknown mutation
1 patient - duplication
40 probands / samples
4 tested positive for mutation
Family size 151 probands + relatives identified
Average: 151/40 = 3.78
Range: 70 (14 to 84) exclude deaths, spouses, 





25 - 29 years old Average eligible persons* per proband 30 - 60 years old
n = 6 36/40 = 0.90 n = 30
Proband 1° 2° 3° 1° 2° 3°
1 0 3 2 11 5 12
include proband & 1st degree relatives include proband & 1st degree relatives
exclude 1 x total colectomy patient Average first degree relative per positive proband exclude 1 x total colectomy patient
11/4 = 2.75
0 patients for intensive Average age = 39 years 12 patients for intensive 
colonoscopy screening colonoscopy screening
Proband
2relatives in relation to proband
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S3 Fig: illustrates the analysis for Strategy 1 and 2 of probands in terms of the tests performed 
and the results; plus the relevant first degree relatives of the LS positive probands. 
See part A: Protocol – Pages 14, 15 & 17   See Part C: Journal Article – page 8 
S3 Fig: Analysis per screening strategy of probands on the DNA database that were tested for LS  
between 01 November 2014 and 30 October 2015, and their relatives
STRATEGY 1: COLONOSCOPY SCREENING ONLY
PROBAND AND 1ST DEGREE RELATIVES
STRATEGY 2: GENETIC TESTING FOR LS FOLLOWED BY COLONOSCOPY FOR LS POSITIVE INDIVIDUALS
18 16 5 1
36 negative 3 positive 1 positive
3 positive 1 positive
3 positive
Exclude probands with POSITIVE FIRST DEGREE RELATIVES 
total colectomies & deaths PLUS POSITIVE PROBANDS (1) 
CRC - Colorectal cancer
* includes 3 patients from the private sector - IHC assumed done
** 6 positive patients: 3 patients with MLH1 mismatch; 2 patients with MSH6 mismatch; 1 patientwith MSH2 mismatch (private sector)
Patient present with CRC 
<50yrs / right-sided lesion /crohns-like response













REVISED BETHESDA CRITERIA FULFILLED (Proband)














Patient present with CRC 
REVISED BETHESDA CRITERIA FULFILLED (Proband)
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S5 Table: Percentage difference in total costs of colonoscopy screening between the base case and  Strategy 
1 and 2 at various discount rates, adherence rates and positivity rates of relatives, presented in 2016 Rand 












in base case 
% change 
in base case 
% change 
in base case 
% change in base 
case 
STRATEGY 1: COLONOSCOPY SCREENING FOR AT RISK PATIENTS 
No discount 56% 38% -8% -54% 
Discount rate 3% 13% ¥Base case  0% -33% -67% 
Discount rate 5% -6% -17% -45% -72% 
STRATEGY 2: GENETIC TESTING AND COLONOSCOPY SCREENING FOR LS DIAGNOSED 
PATIENTS  
50% POSITIVITY RATE OF RELATIVES AT VARIOUS ADHERENCE RATES 
No discount -89% -90% -92% -94% 
Discount rate 3% -91% -92% -93% -95% 
Discount rate 5% -92% -93% -94% -95% 
45% POSITIVITY RATE OF RELATIVES AT VARIOUS ADHERENCE RATES 
No discount -89% -90% -92% -94% 
Discount rate 3% -91% -92% -94% -95% 
Discount rate 5% -92% -93% -94% -95% 
30% POSITIVITY RATE OF RELATIVES AT VARIOUS ADHERENCE RATES 
No discount -92% -92% -94% -95% 
Discount rate 3% -93% -94% -95% -96% 
Discount rate 5% -94% -94% -95% -96% 
 
* Percentage change in base case: [(Cost of alternate case – Cost of base case) ÷ Cost of base case] x 100 
¥ Base case: estimated at a discount rate 3%, adherence rate 75% 
 
S6 Table shows that Strategy 2 (colonoscopy screening combined with genetic testing) costs 
between 89% and 96% less than Strategy 1 (colonoscopy screening only), irrespective of the 
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PARTICIPANT INFORMATION LEAFLET AND CONSENT FORM 
 
TITLE OF THE RESEARCH PROJECT:  
A comparative cost analysis of two screening strategies for colorectal cancer in Lynch 
Syndrome in a tertiary hospital, South Africa. 
 
PRINCIPAL INVESTIGATOR: Dr Edina Sinanovic, Director: School of Public Health & 
Family Medicine: Health Economics Unit, University of Cape Town (UCT), Anzio Road, 
Observatory. 
 
CO-INVESTIGATOR / INTERVIEWER: Ms Yasmina Johnson (MPH: Masters Student), 
Pharmacy Services, 14th floor, 04 Dorp Street, Cape Town, 8001 
CONTACT NUMBER:  Office Hours: 021 483 6198 24 hour number: 084 417 5137 
 
CO-INVESTIGATORS:  
• Prof J Moodley, Cancer Research: Faculty of Health Science; and School of Public Health 
& Family Medicine, UCT, Anzio Road, Observatory 
• Prof P Goldberg, Head: E22 Colorectal Unit, Groote Schuur Hospital, Observatory  
 
I would like to invite you to take part in a research study. The details of the study are presented 
below. Please take some time to read the information which will enable you to decide whether 
you would like to participate or not.  
 
It is very important that you understand what the research involves and how you will be 
involved in the research. If there is any part of the information / study that you do not 
understand clearly, please feel free to ask the person interviewing you to explain this to you. 
 
Your decision to take part in the research is entirely voluntary. This means that you are free to 
decide not to participate and you may also withdraw from the study at any point during the 
study. You do not have to provide a reason for not participating or withdrawing from the study. 
If you decide not to take part in the study or to withdraw from the study, this will not affect you 
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This study has been approved by the Health Research Ethics Committee at the University of 
Cape Town and will be conducted according to the ethical guidelines and principles of the 
international Declaration of Helsinki, South African Guidelines for Good Clinical Practice and 
the Medical Research Council (MRC) Ethical Guidelines for Research. 
 
1. Introduction 
Lynch Syndrome is a genetic disorder that increases an individual’s risk to develop colorectal 
cancer and other cancers. Colorectal cancer is generally asymptomatic (no obvious symptoms 
present) until it has reached an advanced stage and thus an effective screening programme is 
important for early detection and successful management of colorectal cancer. Colonoscopy is 
the only screening programme that has proved to be effective for these individuals.  
 
Furthermore, genetic testing allows for accurate prediction of individuals at high risk of 
colorectal cancer. Thus, using genetic testing, individuals at high risk who will benefit most 
from colonoscopy screening can be identified while those at low risk of disease can be 
excluded from potentially invasive screening procedures.  
 
Preventing or delaying cancer onset, by appropriate screening strategies, will have social as 
well as economic benefits for the country. It is therefore important to establish the affordability 
of such a programme. 
 
2. What is this research study all about? 
The aim of the study is to estimate the cost of two screening options for colorectal cancer for 
individuals with a suspected or confirmed Lynch Syndrome diagnosis. Thus, information related 
to the cost of providing colonoscopy and genetic services will be collected and analysed. 
 
3. Why have you been invited to participate? 
You have been asked to participate in the study because you are involved in providing the 
service, have experience regarding the service or have access to information and costs related 
to the service. 
 
4. What will your responsibilities be? 
You will be asked to provide information regarding the logistics, utilisation, procedures or 
costs of providing the service.  
5. What will the investigator’s / researcher’s responsibilities be? 
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The investigator / researcher will obtain formal permission to access and use the information 
that you provide as well as ethics approval. The researcher will organise suitable meeting times 
with you to obtain the study information. 
 
6. How long will you be expected to participate in the study? 
You may be expected to participate until 28 December 2016 when the study is anticipated to be 
completed. However, your involvement will only be related to the data noted in point 4. 
 
7. Will you benefit from taking part in this research? 
There will be no direct clinical benefit to you from participating in the study. However, the 
results of the study will inform policy-makers regarding affordability of the screening service, 
as well as providing insight into prioritising and allocation of resources. 
 
8. Are there any risks involved in your taking part in this research? 
No risks to you are anticipated as the research focuses on analysing data for costing purposes 
and no human subjects are directly involved. 
 
9. Will you be paid to take part in this study and are there any costs involved? 
You will not receive any payment for participating in the study. You will also not have any 
expenses while participating in the study. The study is self-funded by the researcher. 
 
10. Who will have access to the information that you provide? 
The study team will have access to the information that you provide. Regulatory authorities and 
members of the research ethics committee will have access to the information in order to check that the 
study was conducted properly.  
Information will be captured under unique identifiers (codes) and no names will appear on forms or in 
the database. No identifiers will be used in the analysis or appear in any publication or report. All 
electronic data will be password protected and accessible only to the study team. Paper forms will be 
filed and stored in a locked cabinet.  
Following completion of the study, it will be submitted for the Masters in Public Health: Health 
Economics degree. The findings of the study will also be submitted to the relevant Department of 
Health officials in the Western Cape, UCT Human Genetics department, Groote Schuur hospital and 
persons that participated in the study. A manuscript will be drafted for publication. 
11. Is there anything else that you should know? 
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• You can contact the researcher, Yasmina Johnson, at Tel 021 484-6198 or 084 415 7137 if 
you have any further queries or encounter any problems. 
• You can contact the UCT Health Research Ethics Committee at 021-21 406 6492 if you 
have any concerns or complaints that have not been adequately addressed by the research 
team. 
• You will be provided with a copy of this information and consent form for your own 
records. 
 





DECLARATION BY INFORMANT / INTERVIEWEE: 
 
By signing below, I …………………………………..…………. agree to take part in a 
research study entitled: 
A cost analysis of providing colonoscopy screening versus colonoscopy screening plus genetic 
testing for adults with Lynch Syndrome in a tertiary level care hospital, South Africa. 
 
I declare that: 
• I have read and understood the information and consent form. 
• I have had an opportunity to ask questions and all my questions have been answered 
satisfactorily. 
• I understand that taking part in this study is voluntary and that I have not been coerced 
in any way to take part. 
• I may choose to withdraw from the study at any time and will not be penalised or 
prejudiced in any way. 
 
Signed at (place) ......................…........…………….. on (date) …………....………………. 
 
Signature of participant: __________________________       
 
DECLARATION BY INVESTIGATOR: 
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I (name) ……………………………………………..……… declare that: 
 
• I explained the information in this document to ………………………………… 
• I encouraged him/her to ask questions and took adequate time to explain and answer 
these questions. 
• I am satisfied that he/she understands all aspects of the research adequately, as 
discussed in this information leaflet and consent form. 
 
Signed at (place) ......................…........…………….. on (date) …………....……………….. 
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Submission Guidelines PLoS 
Style and Format 
File format Manuscript files can be in the following formats: DOC, DOCX, RTF, or PDF. Microsoft Word documents 
should not be locked or protected.  
LaTeX manuscripts must be submitted as PDFs. Read the LaTeX guidelines. 
Length Manuscripts can be any length. There are no restrictions on word count, number of figures, or amount of 
supporting information. 
We encourage you to present and discuss your findings concisely. 
Font Use a standard font size and any standard font, except for Symbol font.  
Headings Limit manuscript sections and sub-sections to 3 heading levels. Make sure heading levels are clearly 
indicated in the manuscript text. 
Layout Manuscript text should be double-spaced. 
Do not format text in multiple columns. 
Page and line 
numbers 
Include page numbers and line numbers in the manuscript file. 
Footnotes Footnotes are not permitted. If your manuscript contains footnotes, move the information into the main text 
or the reference list, depending on the content. 
Language Manuscripts must be submitted in English.  
You may submit translations of the manuscript or abstract as supporting information. Read the supporting 
information guidelines. 
Abbreviations Define abbreviations upon first appearance in the text. 
Do not use non-standard abbreviations unless they appear at least three times in the text. 
Keep abbreviations to a minimum. 
Reference 
style 
PLOS uses “Vancouver” style, as outlined in the ICMJE sample references. 
See reference formatting examples and additional instructions below. 
Equations We recommend using MathType for display and inline equations, as it will provide the most reliable 
outcome. If this is not possible, Equation Editor is acceptable. 
Avoid using MathType or Equation Editor to insert single variables (e.g., “a² + b² = c²”), Greek or other 
symbols (e.g., β, Δ, or ′ [prime]), or mathematical operators (e.g., x, ≥, or  ±) in running text. Wherever 
possible, insert single symbols as normal text with the correct Unicode (hex) values. 
Do not use MathType or Equation Editor for only a portion of an equation. Rather, ensure that the entire 
equation is included. Avoid “hybrid” inline or display equations, in which part is text and part is 
MathType, or part is MathType and part is Equation Editor. 
Nomenclature  Use correct and established nomenclature wherever possible. 
Units of measurement Use SI units. If you do not use these exclusively, provide the SI value in parent   each value. Read more about SI units. 
Drugs Provide the Recommended International Non-Proprietary Name (rINN). 
Species names 
Write in italics (e.g., Homo sapiens). Write out in full the genus and species, bo     
of the manuscript and at the first mention of an organism in a paper. After first   
first letter of the genus name followed by the full species name may be used (e    
Genes, mutations, 
genotypes, and alleles 
Write in italics. Use the recommended name by consulting the appropriate gene  
nomenclature database (e.g., HUGO for human genes). It is sometimes advisab    
the synonyms for the gene the first time it appears in the text. Gene prefixes su    
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Manuscript Organization 
Manuscripts should be organized as follows. Instructions for each element appear below the 
list. 
Beginning section The following elements are required, in order: 
• Title page: List title, authors, and affiliations as first page of manuscript 
• Abstract 
• Introduction 
Middle section The following elements can be renamed as needed and presented in any order: 
• Materials and Methods 
• Results 
• Discussion 
• Conclusions (optional) 
Ending section The following elements are required, in order: 
• Acknowledgments 
• References 
• Supporting information captions (if applicable) 
Other elements • Figure captions are inserted immediately after the first paragraph in which the figure 
is cited. Figure files are uploaded separately. 
• Tables are inserted immediately after the first paragraph in which they are cited. 
• Supporting information files are uploaded separately. 
 
Parts of a Submission 
Title 
Include a full title and a short title for the manuscript. 





Specific, descriptive, concise, and 
comprehensible to readers outside the 
field 
Impact of cigarette smoke exposure on innate 
immunity: A Caenorhabditis elegans model 
Solar drinking water disinfection (SODIS) to reduce 






State the topic of the study Cigarette smoke exposure and innate immunity 
SODIS and childhood diarrhoea 
Titles should be written in sentence case (only the first word of the text, proper nouns, and genus 
names are capitalized). Avoid specialist abbreviations if possible. For clinical trials, systematic reviews, 
or meta-analyses, the subtitle should include the study design. 
Author List 
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Authorship requirements  
 
All authors must meet the criteria for authorship as outlined in the authorship policy. Those 
who contributed to the work but do not meet the criteria for authorship can be mentioned in the 
Acknowledgments.  Read more about Acknowledgments.  
 
The corresponding author must provide an ORCID iD at the time of submission by entering it in the user 
profile in the submission system. Read more about ORCID. 
Author names and affiliations 
Enter author names on the title page of the manuscript and in the online submission system. 
On the title page, write author names in the following order: 
• First name (or initials, if used) 
• Middle name (or initials, if used) 
• Last name (surname, family name) 
Each author on the list must have an affiliation. The affiliation includes department, university, or organizational 
affiliation and its location, including city, state/province (if applicable), and country. 
If an author has multiple affiliations, enter all affiliations on the title page only. In the submission system, enter 
only the preferred or primary affiliation. 
Author names will be published exactly as they appear in the manuscript file. Please double-check the 
information carefully to make sure it is correct. 
Corresponding author 
The submitting author is automatically designated as the corresponding author in the submission 
system. The corresponding author is the primary contact for the journal office and the only author able 
to view or change the manuscript while it is under editorial consideration. 
The corresponding author role may be transferred to another coauthor. However, note that transferring 
the corresponding author role also transfers access to the manuscript. (To designate a new 
corresponding author while the manuscript is still under consideration, watch the video tutorial below.) 
Only one corresponding author can be designated in the submission system, but this does not restrict 
the number of corresponding authors that may be listed on the article in the event of publication. 
Whoever is designated as a corresponding author on the title page of the manuscript file will be listed 
as such upon publication. Include an email address for each corresponding author listed on the title 
page of the manuscript. 
Author Contributions 
Enter all author contributions in the submission system during submission. The contributions of all authors must 
be described using the CRediT Taxonomy of author roles. Read the policy. 
Contributions will be published with the final article, and they should accurately reflect contributions to the 
work. The submitting author is responsible for completing this information at submission, and it is expected that 
all authors will have reviewed, discussed, and agreed to their individual contributions ahead of this time. 
PLOS ONE will contact all authors by email at submission to ensure that they are aware of the submission. 
Cover letter 
Upload a cover letter as a separate file in the online system. The length limit is 1 page. 
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The cover letter should include the following information: 
• Summarize the study’s contribution to the scientific literature 
• Relate the study to previously published work 
• Specify the type of article (for example, research article, systematic review, meta-analysis, clinical trial) 
• Describe any prior interactions with PLOS regarding the submitted manuscript 
• Suggest appropriate Academic Editors to handle your manuscript (see the full list of Academic Editors) 
• List any opposed reviewers 
Title page 
The title, authors, and affiliations should all be included on a title page as the first page of the manuscript file.   
Abstract 
The Abstract comes after the title page in the manuscript file. The abstract text is also entered in a separate field in 
the submission system.   
The Abstract should: 
• Describe the main objective(s) of the study 
• Explain how the study was done, including any model organisms used, without methodological detail 
• Summarize the most important results and their significance 
• Not exceed 300 words 
Abstracts should not include: 
• Citations 
• Abbreviations, if possible 
Introduction 
The introduction should: 
• Provide background that puts the manuscript into context and allows readers outside the field to 
understand the purpose and significance of the study 
• Define the problem addressed and why it is important 
• Include a brief review of the key literature 
• Note any relevant controversies or disagreements in the field 
• Conclude with a brief statement of the overall aim of the work and a comment about whether that aim 
was achieved 
Materials and Methods 
The Materials and Methods section should provide enough detail to allow suitably skilled investigators to fully 
replicate your study. Specific information and/or protocols for new methods should be included in detail. If 
materials, methods, and protocols are well established, authors may cite articles where those protocols are 
described in detail, but the submission should include sufficient information to be understood independent of these 
references. 
We encourage authors to submit detailed protocols for newer or less well-established methods as supporting 
information. Read the supporting information guidelines. 
Human or animal subjects and/or tissue or field sampling 
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Methods sections describing research using human or animal subjects and/or tissue or field sampling must include 
required ethics statements. See the reporting guidelines for human research, clinical trials, animal research, and 
observational and field studies for more information. 
Data 
PLOS journals require authors to make all data underlying the findings described in their manuscript fully 
available without restriction, with rare exception. 
Large data sets, including raw data, may be deposited in an appropriate public repository. See our list of 
recommended repositories. 
For smaller data sets and certain data types, authors may provide their data within supporting information 
files accompanying the manuscript. Authors should take care to maximize the accessibility and reusability of the 
data by selecting a file format from which data can be efficiently extracted (for example, spreadsheets or flat files 
should be provided rather than PDFs when providing tabulated data). 
For more information on how best to provide data, read our policy on data availability. PLOS does not accept 
references to “data not shown.” 
Results, Discussion, Conclusions 
These sections may all be separate, or may be combined to create a mixed Results/Discussion section (commonly 
labeled “Results and Discussion”) or a mixed Discussion/Conclusions section (commonly labeled “Discussion”). 
These sections may be further divided into subsections, each with a concise subheading, as appropriate. These 
sections have no word limit, but the language should be clear and concise. 
Together, these sections should describe the results of the experiments, the interpretation of these results, and the 
conclusions that can be drawn. 
Authors should explain how the results relate to the hypothesis presented as the basis of the study and provide a 
succinct explanation of the implications of the findings, particularly in relation to previous related studies and 
potential future directions for research. 
PLOS ONE editorial decisions do not rely on perceived significance or impact, so authors should avoid 
overstating their conclusions. See the PLOS ONE Criteria for Publication for more information. 
Acknowledgments 
Those who contributed to the work but do not meet our authorship criteria should be listed in the 
Acknowledgments with a description of the contribution. 
Authors are responsible for ensuring that anyone named in the Acknowledgments agrees to be named. 
Do not include funding sources in the Acknowledgments or anywhere else in the manuscript file. 
Funding information should only be entered in the financial disclosure section of the submission system. 
References 
Any and all available works can be cited in the reference list. Acceptable sources include: 
• Published or accepted manuscripts 
• Manuscripts on preprint servers, if the manuscript is submitted to a journal and also publicly available as 
a preprint 
Do not cite the following sources in the reference list: 
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• Unavailable and unpublished work, including manuscripts that have been submitted but not yet accepted 
(e.g., “unpublished work,” “data not shown”). Instead, include those data as supplementary material or 
deposit the data in a publicly available database. 
• Personal communications (these should be supported by a letter from the relevant authors but not 
included in the reference list) 
References are listed at the end of the manuscript and numbered in the order that they appear in the text. In the 
text, cite the reference number in square brackets (e.g., “We used the techniques developed by our colleagues [19] 
to analyze the data”). PLOS uses the numbered citation (citation-sequence) method and first six authors, et al. 
Do not include citations in abstracts or author summaries.  
Make sure the parts of the manuscript are in the correct order before ordering the citations. 
Formatting references 
Because all references will be linked electronically as much as possible to the papers they cite, proper 
formatting of the references is crucial.  
PLOS uses the reference style outlined by the International Committee of Medical Journal Editors (ICMJE), also 
referred to as the “Vancouver” style. Example formats are listed below. Additional examples are in the ICMJE 
sample references. 
A reference management tool, EndNote, offers a current style file that can assist you with the formatting 
of your references. If you have problems with any reference management program, please contact the 
source company's technical support. 
Journal name abbreviations should be those found in the National Center for Biotechnology Information 
(NCBI) databases.  
Source Format 
Published articles Hou WR, Hou YL, Wu GF, Song Y, Su XL, Sun B, et al. cDNA, genomic sequence 
cloning and overexpression of ribosomal protein gene L9 (rpL9) of the giant panda 
(Ailuropoda melanoleuca). Genet Mol Res. 2011;10: 1576-1588. 
Devaraju P, Gulati R, Antony PT, Mithun CB, Negi VS. Susceptibility to SLE in South 
Indian Tamils may be influenced by genetic selection pressure on TLR2 and TLR9 
genes. Mol Immunol. 2014 Nov 22. pii: S0161-5890(14)00313-7. doi: 
10.1016/j.molimm.2014.11.005 
Note: A DOI number for the full-text article is acceptable as an alternative to or in 
addition to traditional volume and page numbers. 
Accepted, unpublished 
articles 
Same as published articles, but substitute “Forthcoming” for page numbers or DOI. 
Web sites or online articles Huynen MMTE, Martens P, Hilderlink HBM. The health impacts of globalisation: a 
conceptual framework. Global Health. 2005;1: 14. Available from: 
http://www.globalizationandhealth.com/content/1/1/14. 
Books Bates B. Bargaining for life: A social history of tuberculosis. 1st ed. Philadelphia: 
University of Pennsylvania Press; 1992. 
Book chapters Hansen B. New York City epidemics and history for the public. In: Harden VA, Risse 




prints, or arXiv) 
Krick T, Shub DA, Verstraete N, Ferreiro DU, Alonso LG, Shub M, et al. Amino acid 
metabolism conflicts with protein diversity; 1991. Preprint. Available from: 
arXiv:1403.3301v1. Cited 17 March 2014. 
Published media (print or 
online newspapers and 
magazine articles) 
Fountain H. For Already Vulnerable Penguins, Study Finds Climate Change Is Another 
Danger. The New York Times. 29 Jan 2014. Available from: 
http://www.nytimes.com/2014/01/30/science/earth/climate-change-taking-toll-on-
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Source Format 
penguins-study-finds.html. Cited 17 March 2014. 
New media (blogs, web 
sites, or other written 
works) 
Allen L. Announcing PLOS Blogs. 2010 Sep 1 [cited 17 March 2014]. In: PLOS Blogs 
[Internet]. San Francisco: PLOS 2006 - . [about 2 screens]. Available from: 
http://blogs.plos.org/plos/2010/09/announcing-plos-blogs/. 
Masters' theses or doctoral 
dissertations 
Wells A. Exploring the development of the independent, electronic, scholarly journal. 
M.Sc. Thesis, The University of Sheffield. 1999. Available from: 
http://cumincad.scix.net/cgi-bin/works/Show?2e09 
Databases and repositories 
(Figshare, arXiv) 
Roberts SB. QPX Genome Browser Feature Tracks; 2013 [cited 2013 Oct 5]. Database: 
figshare [Internet]. Available from: 
http://figshare.com/articles/QPX_Genome_Browser_Feature_Tracks/701214. 
Multimedia (videos, 
movies, or TV shows) 
Hitchcock A, producer and director. Rear Window [Film]; 1954. Los Angeles: MGM. 
Supporting Information 
Authors can submit essential supporting files and multimedia files along with their manuscripts. All supporting 
information will be subject to peer review. All file types can be submitted, but files must be smaller than 10 MB in 
size. 
Authors may use almost any description as the item name for a supporting information file as long as it contains 
an “S” and number. For example, “S1 Appendix” and “S2 Appendix,” “S1 Table” and “S2 Table,” and so forth.   
Supporting information files are published exactly as provided, and are not copyedited. 
Supporting information captions 
List supporting information captions at the end of the manuscript file. Do not submit captions in a separate file. 
The file number and name are required in a caption, and we highly recommend including a one-line title as well. 
You may also include a legend in your caption, but it is not required. 
Example caption 
 
S1 Text. Title is strongly recommended. Legend is optional. 
In-text citations 
We recommend that you cite supporting information in the manuscript text, but this is not a requirement. If you 
cite supporting information in the text, citations do not need to be in numerical order. 
Read the supporting information guidelines for more details about submitting supporting information and 
multimedia files. 
Figures and Tables 
Figures 
Do not include figures in the main manuscript file. Each figure must be prepared and submitted as an individual 
file. 
Cite figures in ascending numeric order upon first appearance in the manuscript file. 
Read the guidelines for figures. 
Figure captions 
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Figure captions must be inserted in the text of the manuscript, immediately following the paragraph in which the 
figure is first cited (read order). Do not include captions as part of the figure files themselves or submit them in a 
separate document. 
At a minimum, include the following in your figure captions: 
• A figure label with Arabic numerals, and “Figure” abbreviated to “Fig” (e.g. Fig 1, Fig 2, Fig 3, etc). 
Match the label of your figure with the name of the file uploaded at submission (e.g. a figure citation of 
“Fig 1” must refer to a figure file named “Fig1.tif”). 
• A concise, descriptive title 
The caption may also include a legend as needed. 
Read more about figure captions. 
Tables 
Cite tables in ascending numeric order upon first appearance in the manuscript file. 
Place each table in your manuscript file directly after the paragraph in which it is first cited (read order). Do not 
submit your tables in separate files. 
Tables require a label (e.g., “Table 1”) and brief descriptive title to be placed above the table. Place legends, 
footnotes, and other text below the table.  
Read the guidelines for tables. 
Data reporting 
All data and related metadata underlying the findings reported in a submitted manuscript should be deposited in an 
appropriate public repository, unless already provided as part of the submitted article. 
Read our policy on data availability. 
Repositories may be either subject-specific (where these exist) and accept specific types of structured data, or 
generalist repositories that accept multiple data types. We recommend that authors select repositories appropriate 
to their field. Repositories may be subject-specific (e.g., GenBank for sequences and PDB for structures), general, 
or institutional, as long as DOIs or accession numbers are provided and the data are at least as open as CC BY. 
Authors are encouraged to select repositories that meet accepted criteria as trustworthy digital repositories, such as 
criteria of the Centre for Research Libraries or Data Seal of Approval. Large, international databases are more 
likely to persist than small, local ones. 
See our list of recommended repositories. 
To support data sharing and author compliance of the PLOS data policy, we have integrated our submission 
process with a select set of data repositories. The list is neither representative nor exhaustive of the suitable 
repositories available to authors. Current repository integration partners 
include Dryad and FlowRepository. Please contact data@plos.org to make recommendations for further 
partnerships. 
Instructions for PLOS submissions with data deposited in an integration partner repository: 
• Deposit data in the integrated repository of choice. 
• Once deposition is final and complete, the repository will provide you with a dataset DOI (provisional) 
and private URL for reviewers to gain access to the data. 
• Enter the given data DOI into the full Data Availability Statement, which is requested in the Additional 
Information section of the PLOS submission form. Then provide the URL passcode in the Attach Files 
section. 
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If you have any questions, please email us. 
Accession numbers 
All appropriate data sets, images, and information should be deposited in an appropriate public repository. See our 
list of recommended repositories. 
Accession numbers (and version numbers, if appropriate) should be provided in the Data Availability Statement. 
Accession numbers or a citation to the DOI should also be provided when the data set is mentioned within the 
manuscript. 
In some cases authors may not be able to obtain accession numbers of DOIs until the manuscript is accepted; in 
these cases, the authors must provide these numbers at acceptance. In all other cases, these numbers must be 
provided at submission. 
Identifiers 
As much as possible, please provide accession numbers or identifiers for all entities such as genes, proteins, 
mutants, diseases, etc., for which there is an entry in a public database, for example: 
• Ensembl 
• Entrez Gene 
• FlyBase 
• InterPro 
• Mouse Genome Database (MGD) 
• Online Mendelian Inheritance in Man (OMIM) 
• PubChem 
Identifiers should be provided in parentheses after the entity on first use. 
Additional Information Requested at Submission 
Funding statement 
This information should not be in your manuscript file; you will provide it via our submission system. 
This information will be published with the final manuscript, if accepted, so please make sure that this is accurate 
and as detailed as possible. You should not include this information in your manuscript file, but it is important to 
gather it prior to submission, because your financial disclosure statement cannot be changed after initial 
submission. 
Your statement should include relevant grant numbers and the URL of any funder's web site. Please also state 
whether any individuals employed or contracted by the funders (other than the named authors) played any role in: 
study design, data collection and analysis, decision to publish, or preparation of the manuscript. If so, please name 
the individual and describe their role. 
Competing interests 
This information should not be in your manuscript file; you will provide it via our submission system. 
All potential competing interests must be declared in full. If the submission is related to any patents, patent 
applications, or products in development or for market, these details, including patent numbers and titles, must be 
disclosed in full. 
Manuscripts disputing published work 
23 
PART D: Appendices 
For manuscripts disputing previously published work, it is PLOS ONE policy to invite a signed review by the 
disputed author during the peer review process. This procedure is aimed at ensuring a thorough, transparent, and 
productive review process. 
If the disputed author chooses to submit a review, it must be returned in a timely fashion and contain a full 
declaration of all competing interests. The Academic Editor will consider any such reviews in light of the 
competing interest. 
Authors submitting manuscripts disputing previous work should explain the relationship between the manuscripts 
in their cover letter, and will be required to confirm that they accept the conditions of this review policy before the 
manuscript is considered further. 
Related manuscripts 
Upon submission, authors must confirm that the manuscript, or any related manuscript, is not currently under 
consideration or accepted elsewhere. If related work has been submitted to PLOS ONE or elsewhere, authors must 
include a copy with the submitted article. Reviewers will be asked to comment on the overlap between related 
submissions. 
We strongly discourage the unnecessary division of related work into separate manuscripts, and we will not 
consider manuscripts that are divided into “parts.” Each submission to PLOS ONE must be written as an 
independent unit and should not rely on any work that has not already been accepted for publication. If related 
manuscripts are submitted to PLOS ONE, the authors may be advised to combine them into a single manuscript at 
the editor's discretion. 
PLOS does support authors who wish to share their work early and receive feedback before formal peer review. 
Deposition of manuscripts with preprint servers does not impact consideration of the manuscript at any PLOS 
journal. 
Authors choosing bioRxiv may now concurrently submit directly to select PLOS journals through bioRxiv’s direct 
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• Individuals with Lynch Syndrome (LS) have a high risk for colorectal cancer and 
the onset of cancer occurs at ages when persons are economically active and 
support families.  
• South African families with LS have been implicated with the MMR genes, MLH1 
and MSH2, which presents the highest risks (40% to 70%) for colorectal cancer 
(Giardiello et al. 2014; Snowsill et al. 2014; Vasen et al. 2013).  
• Colonoscopy reduced the incidence of colorectal cancer in individuals with LS by 
62% and mortality by 65% to 70% (Palomaki et al. 2009; Vasen et al 2013; 
Snowsill et al. 2014). 
• Colonoscopy screening combined with genetic testing significantly reduced the 
number of persons requiring intensive colonoscopy; and consequently was 92% 
less costly than performing colonoscopy screening only i.e. R4 932 718 ($332 617) 
compared to R390 308 ($26 319). 
• This vast cost difference between the two strategies (colonoscopy only and 
colonoscopy + genetic testing) was not sensitive to discount rates, adherence rates 
or positivity rates of relatives. 
 
Introduction 
Lynch Syndrome, an autosomal dominant cancer syndrome, is associated with high risks 
for colorectal cancer, endometrial cancer and certain other cancers as a result of a mutation 
in one of the DNA mismatch repair (MMR) genes (Vasen et al. 2013). Mutation carriers 
have a lifetime risk for colorectal cancer of 25% to 75%, compared to a lifetime risk of 5% 
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in the general population (Bonadona et al. 2011; Giardiello et al. 2014; Snowsill et al. 
2014; Vasen et al 2013). The highest risks are associated with MLH1 and MSH2 (40% to 
70%), with lower risks associated with MSH6 (10% to 22%) (Bonadona et al. 2011; 
Giardiello et al. 2014; Snowsill et al. 2014; Vasen et al 2013). The individuals included in 
this study were predominantly carriers of MLH1 and MSH2 mutations. Due to the 
autosomal dominant pattern, LS-associated mutations have a 50% chance of being passed 
on to a first degree relative (FDR) (Snowsill et al. 2014). FDRs (i.e. children, siblings or 
parents) of a mutation carrier are, therefore, considered as high risk for LS. Furthermore, 
colorectal cancers associated with Lynch Syndrome generally occur before the age of 50 
years and thus, includes persons that are financially independent, economically active and 
support families (Snowsill et al. 2014). Thus, preventing or delaying cancer onset, by 
appropriate screening strategies, will have social as well as economic benefits for the 
country.  
Colonoscopy is the only proven effective screening programme for colorectal cancer in LS; 
reducing colorectal cancer incidence by 62% and mortality by 65% to 70% (Palomaki et al. 
2009; Vasen et al. 2013; Snowsill et al. 2014). Colonoscopy allows for (1) early detection 
of cancer and thus improved chances of curative treatment; and (2) pre-cancerous lesions 
to be removed before the polyps progress to cancer (EGAPP 2009; Giardello et al 2014). 
For LS, biennial colonoscopy (for individuals under 30 years old) and annual colonoscopy 
(for individuals between 30 years to 60 years old) were recommended (Snowsill et al. 
2014; Vasen et al. 2013).  
Due to limited resources in the public sector in South Africa, colonoscopies are generally 
reserved for patients that already present with symptoms. (Thomson: GIT clinic GSH, 
personal communication 2015). Identifying individuals at high risk of colorectal cancer 
who will benefit from colonoscopy screening and leaving those at low risk of disease 
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unexposed to potentially invasive screening procedures, will reduce the number of 
unnecessary colonoscopies; as well as direct the use of scarce resources more appropriately 
(Snowsill et al. 2014). Genetic testing for Lynch Syndrome is a cost-effective and reliable 
strategy to identify individuals for colonoscopy screening (EGAPP 2009; Snowsill, et al. 
2014). Currently, genetic testing for LS is offered via a research interface with the 
University of Cape Town (Ramesar: Human Genetics UCT, personal communication 
2014). 
Colonoscopy screening and clinical genetics have a strong emphasis on prevention of 
cancers which supports the Western Cape Department of Health’s strategic objective of 
enhanced wellness through primary, secondary and tertiary prevention (Department of 
Health: Western Cape. 2014). Furthermore, results from this study would inform on the 
development of the genetic services policy framework (Department of Health: Circular 
H212/2014) in terms of resource requirements and affordability of implementing an 
effective Lynch Syndrome genetic testing programme.  
Published data on the cost implications associated with providing a formal colonoscopy 
and genetic testing screening service for patients with Lynch Syndrome in South Africa is 
not available. Studies conducted in high income countries are not generalisable to South 
Africa (Snowsill et al. 2014) as cost-effectiveness is context specific and linked to 
available resources. (Drummond et al. 2005). This study, therefore, estimated and 
compared the cost of two colonoscopy screening options for colorectal cancer from a 
health provider’s perspective i.e. the cost of intensive colonoscopy for all LS and LS 
suspected individuals was compared to the cost of intensive colonoscopy only for 
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Objectives 
• The average unit cost of colonoscopy was estimated. 
• The average unit cost for genetic testing for diagnosing a proband and a relative 
with LS was estimated.  
• The total numbers of colonoscopies required per strategy were projected.  




A comparative cost analysis of two screening approaches was conducted from the service 
provider perspective at a tertiary hospital. A total of 40 probands that fulfilled the Revised 
Bethesda Criteria and were selected for genetic testing between 01 November 2014 and 30 
October 2015, and their relatives were assessed. From this cohort, all probands and their 
FDRs were analysed according to Strategy 1 (colonoscopy only). From the same cohort, 
probands that tested positive for a mutation and their FDRs were analysed according to 
Strategy 2 (genetic testing and colonoscopy). Total costs for the two screening strategies 
were compared. Sensitivity analyses were performed on adherence rates to colonoscopy, 
positivity rates of relatives and discount rates. 
Key findings:  
• Colonoscopy screening combined with genetic testing was 90% less costly than 
performing colonoscopy screening only i.e. R4 932 718 ($332 617) compared to 
R390 308 ($26 319). The cost difference between the two strategies was not 
influenced by discount rates, adherence rates or positivity rates of relatives. 
• The unit cost of colonoscopy was R3 394.29 ($228.88); and with genetic 
counselling included it was R3 484.09 ($234.94). 
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• The weighted average unit cost for diagnosing a proband was R3 913 ($264) and 
for diagnosing a relative it was R1 300 ($88). The total cost for the cohort related to 
the genetic testing process was R170 805 ($11 518). 
• It would cost R39 127 ($2 638) to exclude nine out of ten probands from the 
physical, psychological and financial implications of lifetime colonoscopy; while 
identifying one proband with confirmed LS. 
• At a 50% positivity rate of relatives, it would cost R2 600 ($175) to exclude one 
FDR from lifetime colonoscopy while diagnose one FDR with LS. At a 30% 
positivity rate of relatives it would cost R3 900 ($262) to exclude two out three 
FDRs from lifetime colonoscopy; while identifying one FDR with LS. 
 
Policy recommendations 
• Implementation of a colonoscopy screening programme combined with genetic 
testing reduces the need for intensive colonoscopy on a large number of 
individuals; thus reducing the cost of colonoscopy screening. Also, a large number 
of low risk individuals would be saved from exposure to the physical and 
psychological hazards of colonoscopy. 
• Colonoscopy services should be effective and accessible as genetic testing offers 
limited benefit without a well-functioning colonoscopy screening service.  
• Genetic testing of relatives is less costly than diagnosing a proband and may be of 
greater benefit as the relative is more likely not to have cancer. Testing of relatives 
should, therefore, be strongly encouraged and accessibility to genetic testing 
services should be facilitated. 
• Research with regards to the effectiveness of the screening programme should be 
conducted and this should involve a national register for Lynch Syndrome. 
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